

**A Phase II Pilot Trial Of Paclitaxel Protein Bound  
Plus Cisplatin Plus Gemcitabine and the Addition Of Paricalcitol Upon  
Stable or Progressive Disease in Patients With Previously Untreated  
Metastatic Pancreatic Ductal Adenocarcinoma (NABPLAGEMD)**

<b>IND Exempt</b>	
<b>SPONSOR</b> <b>HonorHealth Research Institute</b>	
BRIEF PROTOCOL TITLE: PACLITAXEL PROTEIN BOUND PLUS CISPLATIN PLUS GEMCITABINE AND PARICALCITOL FOR PANCREATIC ADENOCARCINOMA (NABPLAGEMD) Amendment 1, Version 2.0, Version Date 25 October 2018 Original Protocol, Version 1.0, VERSION DATE 08 January 2018	
<b>Lead Principal Investigator:</b> Erkut Borazanci, MD, MS Honor Health Research Institute 10510 N. 92 <sup>nd</sup> St. Scottsdale, AZ 85258 Fax: 480-323-1359 Email: <a href="mailto:Erkut.Borazanci@honorhealth.com">Erkut.Borazanci@honorhealth.com</a>	<b>Consulting Investigator:</b> Daniel D. Von Hoff, MD, FACP Chief Scientific Officer HonorHealth Research Institute Physician in Chief, Distinguished Professor Translational Genomics Research Institute (TGen) 445 N. Fifth Street. Phoenix, AZ 85004 Tel. 602-343-8492 <a href="mailto:dvh@tgen.org">dvh@tgen.org</a>

*This study is funded and supported by the research teams at:*



*Funding Provided By: CRUK SU2C Lustgarten Foundation Dream Team Grant*

**CONFIDENTIAL**

The information contained in this document is confidential and the proprietary property of HonorHealth. Any unauthorized use or disclosure of such information without the prior written authorization of HonorHealth is prohibited.

## STUDY CONTACTS

### Funders

---

Stand Up To Cancer/CRUK/Lustgarten Foundation (Ref: SU2C-AACR-D7-20-16)

### EU Legal Representative

---

Sally Burtles, Director of Research Services & Business Development, Joint Research Management Office (JRMO), Barts Health NHS Trust, QM Innovation Building, 5 Walden Street, London, E1 2EF, UK. Tel: +44(0)20 7882 7260, Fax: +44(0)20 7882 7276, Email: [sponsorsrep@bartshealth.nhs.uk](mailto:sponsorsrep@bartshealth.nhs.uk)

### Chief Clinical Collaborators

---

Erkut Borazanci MD, MS Medical Oncology/Clinical Investigator, HonorHealth Research Institute, 10510 N. 92nd Street, Ste. #200, Scottsdale, AZ, 85258, USA. Tel: +1 480-323-1350, E: [erkut.borazanci@honorhealth.com](mailto:erkut.borazanci@honorhealth.com)

Andrew Lowy MD, FACS. University of California, San Diego, 9500 Gillman Dr #0987, La Jolla, CA 92093 [alow@ucsd.edu](mailto:alow@ucsd.edu)

Gayle S. Jameson, MSN, ACNP-BC, AOCN Honor Health Research Institute 10510 N. 92nd Street, Ste. #200 Scottsdale, AZ 85258, USA. Tel: 480-323-1350, E: [gayle.jameson@honorhealth.com](mailto:gayle.jameson@honorhealth.com)

Daniel D. Von Hoff, MD, FACP, Chief Scientific Officer HonorHealth Research Institute, Physician in Chief, Distinguished Professor Translational Genomics Research Institute (TGen), 10510 N. 92nd Street Scottsdale, AZ 85258, USA. Tel: 480-323-1350, E: [dvh@tgen.org](mailto:dvh@tgen.org)

David Propper, MD, PhD, Medical Oncologist, Barts Health NHS Trust, Queen Mary University of London, Barts Cancer Institute, Old Anatomy Building, Charterhouse Square, London, EC1M 6BQ, UK, Tel: +44(0)20 7882 8272, Fax: +44(0)20 7882 8409, E: [d.j.propper@qmul.ac.uk](mailto:d.j.propper@qmul.ac.uk)

Hitendra Patel, MD, Associate Clinical Professor of Medicine, Moores Cancer Centre, University of California San Diego, 3855 Health Sciences Drive, MC 0987 La Jolla, CA 92093, USA. Tel: +1 (858) 822-3115, E: [hip003@ucsd.edu](mailto:hip003@ucsd.edu)

P. O'Dwyer, MD, Professor of Medicine, Abramson Cancer Center, University of Pennsylvania, PCAM 7 South, USA E: [Peter.O'Dwyer@uphs.upenn.edu](mailto:Peter.O'Dwyer@uphs.upenn.edu)

### Study Statistician

---

Kevin P Gosselin PhD, Director, Academics & Biostatistics, HonorHealth Research Institute, 10510 N. 92nd Street, Suite 300, Scottsdale, AZ 85258, F: (480) 323-3208  
P: (480) 323-3251, E: [Kevin.Gosselin@honorhealth.com](mailto:Kevin.Gosselin@honorhealth.com)

### Pharmacodynamic and translational endpoint analysis

---

#### Stem Cells:

Christopher Heeschen, Centre for Stem Cells in Cancer & Ageing, Barts Cancer Institute, Queen Mary University of London, John Vane Science Centre, Charterhouse Square, London, EC1M 6BQ, UK E: [c.heeschen@qmul.ac.uk](mailto:c.heeschen@qmul.ac.uk)

**Stellate cell biology:**

Michael Downes PhD, Gene Expression Laboratory, Salk Institute for Biological Sciences, 10010 N Torrey Pines Rd, La Jolla, CA 92037, USA. E: [downes@salk.edu](mailto:downes@salk.edu)

Morgan Truitt, PhD, Salk Institute 10010 N Torrey Pines Rd, La Jolla, CA 92037  
Tel. 858-453-4100, [truitt@salk.edu](mailto:truitt@salk.edu)

Michael T. Barrett, PhD, Associate Consultant II, Department of Research, Mayo Clinic Arizona, MCCRb Cr2-111, 13400 East Shea Boulevard, Scottsdale, AZ 85259, 480-301-6736, [barrett.michael@mayo.edu](mailto:barrett.michael@mayo.edu)

**Tumour metabolism:**

Josh Rabinowitz MD, Chemistry and Integrative Genomics, Carl Icahn Laboratory, Rm. 241, Washington Road, Princeton University, Princeton, NJ 08544, USA. E: [josh@genomics.princeton.edu](mailto:josh@genomics.princeton.edu)

**Imaging sub-study**

Ron Korn MD, PhD, Imaging Endpoints, 9700 N. 91<sup>st</sup> St, STE B-200, Scottsdale, AZ, 85258, USA. E: [rkorn@imagingendpoints.com](mailto:rkorn@imagingendpoints.com)

**Tissue Banking**

Barts Pancreas Tissue Bank (REC Ref: 13/SC/0592, HTA Licensing number: 12199), Barts Cancer Institute, Queen Mary University of London, John Vane Science Centre, Charterhouse Square, London, EC1M 6BQ, UK

TGen Tissue Repository (TGen Protocol #mdemeure12-034; Western Institutional Review Board Protocol #20121959), Translational Genomics Research Institute (TGen), 445 N. Fifth St., Phoenix, AZ 85004, USA

**USA Coordinating Office**

Brandy Carothers, Regulatory Affairs Coordinator, HonorHealth Research Institute  
10510 N. 92<sup>nd</sup> St., Suite 200, Scottsdale, AZ 85258, Tel. 480-323-1323, E: [Brandy.Carothers@HonorHealth.com](mailto:Brandy.Carothers@HonorHealth.com) or [HRIRegulatoryAffairs@honorhealth.com](mailto:HRIRegulatoryAffairs@honorhealth.com)

**UK Coordinating Office**

Centre for Experimental Cancer Medicine, Barts Cancer Institute, Queen Mary university of London, Old Anatomy Building, Charterhouse Square, London, EC1M 6BQ, UK. Email: , Tel: +44(0)20 7882 8197, Fax: +44(0)20 7882 8409

**Participating Sites**

---

A list of participating sites can be obtained from the Trial Coordinator.

**Key Protocol Development Team**

---

**Erkut Borazanci** MD, MS Medical Oncology/Clinical Investigator, HonorHealth, 10510 N. 92nd Street, #200, Scottsdale, AZ, 85258. E: [erkut.borazanci@honorhealth.com](mailto:erkut.borazanci@honorhealth.com)

**Andrew Lowy** MD, FACS. University of California, San Diego, 9500 Gillman Dr #0987, La Jolla, CA 92093, E: [alowy@ucsd.edu](mailto:alowy@ucsd.edu)

David Propper, MD, PhD, Medical Oncologist, Barts Health NHS Trust, Queen Mary University of London, Barts Cancer Institute, Old Anatomy Building, Charterhouse Square, London, EC1M 6BQ, UK, Tel: +44(0)20 7882 8272, Fax: +44(0)20 7882 8409, E: [d.j.propper@qmul.ac.uk](mailto:d.j.propper@qmul.ac.uk)

Daniel D. Von Hoff, MD, FACP, Chief Scientific Officer HonorHealth Research Institute, Physician in Chief, Distinguished Professor Translational Genomics Research Institute (TGen), 10510 N. 92nd Street Scottsdale, AZ 85258, USA. Tel: 480-323-1350, E: [dvh@tgen.org](mailto:dvh@tgen.org)

**K. Mousa**, Project Manager – Global Trial Set Up, Centre for Experimental Cancer Medicine, Barts Cancer Institute, Queen Mary University of London, London, UK. E: [k.mousa@qmul.ac.uk](mailto:k.mousa@qmul.ac.uk)

**Dr S-J .Sarker**, Statistician, Centre for Experimental Cancer Medicine, Barts Cancer Institute, Queen Mary University of London, London, UK. E: [s.sarker@qmul.ac.uk](mailto:s.sarker@qmul.ac.uk)

## INVESTIGATOR PROTOCOL AGREEMENT

Protocol#: SU2C HRI NPG-002

Protocol Title: A Phase II Pilot Trial of Paclitaxel protein bound plus Cisplatin plus Gemcitabine And The Addition of Paricalcitol upon Disease Stable or Progressive in Patients with Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma

Protocol Version/Date: Version 2.0, 11 Oct 2018

**I confirm that my staff and I have carefully read and understand this protocol. I/we agree to comply with the procedures and terms of the clinical trial specified herein. In particular, I/we have agreed to:**

- Abide by all obligations as required by local and federal regulatory authorities.
- Comply with Good Clinical Practice (GCP) and all applicable regulatory requirements.
- Maintain confidentiality and assure security of Sponsor and SU2C confidential documents
- Obtain Institutional Review Board (IRB) approval of the protocol, any amendment to the protocol, and periodic re-approval as required, and to keep the IRB informed of any adverse events and periodically report the status of the trial to them.
- Not implement any deviations from or changes to the protocol without agreement from the sponsor and prior review and written approval from the IRB, except where necessary to eliminate an immediate hazard to the patients or for administrative aspects of the trial (where permitted by all applicable regulatory requirements).
- Assure that each patient enrolled into the trial has read, understands, and has signed the informed consent.
- Ensure that I and all persons assisting me with the trial are adequately informed and trained about the investigational drug and of their trial-related duties and functions as described in the protocol.
- Make prompt reports of serious adverse events (SAEs) and deaths within 24 hours of discovery to Sponsor.
- Assure access by Sponsor including assigned CRO and/or FDA to original source documents.
- Prepare and maintain adequate and accurate case histories designed to record all observations and other data pertinent to the investigation on each individual treated in the investigation.
- Arrange for the transfer of appropriate data from case histories to case report forms for the collection and transmission of data to the Sponsor.
- Retain records and documents related to this trial for at least 3 years after the completion of the trial as confirmed by the sponsor.
- Cooperate fully with any trial-related GCP audit as performed by the assurance group specified by the Sponsor.
- Abide by the stipulations in the Disclosure of Data section and the manuscript preparation/authorship guidelines established at the outset of the trial.

Investigator's Printed Name: \_\_\_\_\_

Investigator' Signature: \_\_\_\_\_ Date: \_\_\_\_\_

## SAE REPORTING

All SAEs must be reported promptly to HonorHealth after the Investigator determines that the event meets the criteria for an SAE. For life-threatening or fatal events, the Investigator must report the event within 24 hours of discovery of the SAE by email or fax using the contact information below.

HonorHealth Drug Safety Team  
24 Hour Phone #: 480-323-1350  
Fax # : 480-323-1560  
Email: [DrugSafety@honorhealth.com](mailto:DrugSafety@honorhealth.com)

For any additional questions regarding reporting requirements of a SAE, please contact:

Brandy Carothers  
Regulatory Affairs Coordinator  
HonorHealth Research Institute  
Tel. 480-323-1323  
E: [Brandy.Carothers@HonorHealth.com](mailto:Brandy.Carothers@HonorHealth.com) or [HRIRegulatoryAffairs@honorhealth.com](mailto:HRIRegulatoryAffairs@honorhealth.com)

<b>1 BACKGROUND .....</b>	<b>11</b>
1.1 Potential Risks of Paclitaxel Protein Bound .....	12
1.2 Potential risks of cisplatin .....	12
1.3 Potential Risks of Gemcitabine .....	13
1.4 Rationale and Potential Risks of Paricalcitol .....	13
1.4.1 Potential risks of paricalcitol .....	14
1.5 Potential risks of paclitaxel protein bound plus Gemcitabine .....	14
1.6 Potential risks of paclitaxel protein bound, plus Cisplatin, plus Gemcitabine .....	14
1.7 Study and Dose Rationale .....	15
1.8 Sequence of Drug Administration and Rationale .....	15
<b>2 OBJECTIVES .....</b>	<b>16</b>
2.1 Primary Objective .....	16
2.2 Secondary Objectives .....	16
2.3 Overview .....	16
2.4 Primary Endpoints .....	16
2.5 Secondary Endpoints .....	16
<b>3 STUDY POPULATION .....</b>	<b>17</b>
3.1 Patient Selection and Study Duration .....	17
3.2 Inclusion Criteria .....	17
3.3 Exclusion Criteria .....	17
3.4 Patient Enrollment .....	18
3.5 Patient Discontinuation .....	18
3.6 Study Discontinuation .....	18
<b>4 STUDY TREATMENT .....</b>	<b>19</b>
4.1 Administration and Dosing .....	19
4.2 Body Surface Area Calculation .....	19
4.3 Dose Modification for Toxicity .....	19
Table 1 Dose Reduction Schema .....	20
4.3.1 Hematological Toxicity .....	20
4.3.1.1 Dose Modifications at Day 1 .....	20
Table 2 Dose Modifications for Day 1 of Each Cycle (Hematologic Toxicity) .....	20
4.3.1.2 Dose Adjustments within a Treatment Cycle .....	20
Table 3 Dose Modification for Day 8 of Each Cycle (Hematologic Toxicity)* .....	21
4.3.2 Non-hematological Toxicity .....	21

Table 4. Paclitaxel protein bound and gemcitabine and cisplatin Dose Modifications for Day 1 of Each Cycle (Non-hematologic Toxicity)* .....	22
--	----


<b>Table 5. Paclitaxel protein bound and gemcitabine and cisplatin Dose Modifications Day 8 Each Cycle (Non-hematological Toxicity) .....</b>	<b>22</b>
---	-----------

4.3.2.1 Peripheral Neuropathy .....	22
4.3.2.2 Nephrotoxicity .....	22
4.3.2.3 Cutaneous Toxicity .....	22
4.3.2.4 Gastrointestinal Toxicity .....	23
4.3.2.5 Pulmonary Embolism .....	23
4.3.2.6 Interstitial Pneumonitis .....	23
4.3.2.7 Hypersensitivity Reactions .....	23
4.3.2.8 Colony Stimulating Factors .....	24
4.3.2.9 Prophylaxis against Sepsis .....	24
4.3.2.10 Hypercalemia .....	24
4.4 Intended Dose Delays .....	24
4.5 Concomitant Therapy .....	24
4.6 Concomitant Therapies Requiring Caution .....	25
<b>5 STUDY ASSESSMENTS .....</b>	<b>25</b>
5.1 Laboratory Assessments .....	25
5.2 Screening (Within 21 Days Prior to First Dose) .....	25
5.3 On-Study Assessments .....	26
5.4 End of Treatment .....	28
5.5 Follow-Up Assessments after End of Study or Early Termination .....	29
5.6 Statistical Considerations .....	29
5.7 Treatment Assignment .....	29
5.8 Patient Disposition .....	29
5.9 Patient Characteristics .....	29
5.10 Efficacy Analysis .....	30
5.11 Safety Analysis .....	30
5.12 Replacement of Patients .....	30
5.13 Quality Assurance .....	30
5.14 Chain of Custody of Biological Samples .....	30
<b>6 EVALUATION OF RESPONSE .....</b>	<b>31</b>
6.1 Best Overall Response .....	31
6.2 Overall Tumor Response .....	31



6.3	Not Evaluable .....	31
6.4	Progression-free Survival .....	31
6.5	Survival .....	32
6.6	Analysis Plan.....	32
6.7	Guidelines for Measuring Disease .....	32
6.8	Disease Definitions.....	32
6.9	Methods of Measurement.....	33
6.10	Baseline Documentation of “Target” and “Non-target” Lesions .....	33
6.11	Response Criteria.....	34
Table 6. RECIST Target Lesion Response Criteria.....		34
Table 7. RECIST Non-target Lesion Response Criteria .....		34
6.12	Evaluation of Best Overall Response .....	35
Table 8. RECIST Overall Response Criteria .....		35
6.13	Duration of Overall Response.....	35
6.14	Duration of Stable Disease .....	36
<b>7</b>	<b>SAFETY .....</b>	<b>36</b>
7.1	Adverse Events .....	36
7.2	Serious Adverse Events .....	37
7.3	Adverse Event Severity .....	37
7.4	Causality Assessment .....	37
7.5	Safety and Tolerance Analysis .....	37
7.5.1	Laboratory Assessments .....	38
7.5.1.1	Hematology Parameters .....	38
7.5.1.2	Clinical Chemistry .....	38
7.5.1.3	Peripheral Neuropathy .....	38
7.6	Patient Reporting of AEs and SAEs.....	38
7.7	Investigator Reporting Serious Adverse Events.....	38
7.8	IRB Notification of SAEs.....	39
7.9	SAE Follow-Up.....	39
7.10	Sponsor Notification of Post-Study SAEs .....	40
7.11	Pregnancy .....	40
<b>8</b>	<b>ETHICAL, LEGAL, AND ADMINISTRATIVE ASPECTS.....</b>	<b>40</b>
8.1	Ethics .....	40
8.1.1	Institutional Review Board/Ethics Committee Approval .....	40
8.1.2	Ethical Conduct of the Study.....	40

8.1.3	Informed Consent .....	41
8.1.4	Data Safety and Monitoring.....	41
8.2	Disclosure of Data .....	41
8.2.1	Study Data Monitoring Plan .....	41
8.2.2	Confidentiality .....	42
8.2.3	Publication .....	42
8.3	Protocol Compliance .....	43
8.4	On-site Audits.....	43
8.5	Premature Closure of the Study .....	43
8.6	Investigator Documentation .....	43
8.6.1	Form FDA 1572 .....	43
8.6.2	Curriculum Vitae .....	43
8.6.3	Financial Disclosures .....	44
8.6.4	Laboratory Certification and Normal Ranges .....	44
8.7	Records Retention.....	44
8.8	Protocol Deviations .....	44
<b>9</b>	<b>DATA MANAGEMENT .....</b>	<b>44</b>
9.1	Patient Enrollment Instructions .....	44
9.2	Data Submission Instructions .....	44
<b>10</b>	<b>TERMINATION OF STUDY .....</b>	<b>45</b>
<b>11</b>	<b>INVESTIGATOR'S PROTOCOL AGREEMENT .....</b>	<b>45</b>
<b>12</b>	<b>REFERENCES.....</b>	<b>45</b>
<b>13</b>	<b>APPENDICES.....</b>	<b>49</b>
	APPENDIX A: Schedule of Events.....	49
	APPENDIX B: KARNOFSKY PERFORMANCE STATUS .....	53
	Appendix C: List of Abbreviations.....	54
	APPENDIX D: Revised National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 4.0 (published 28 May 2009) .....	58
	APPENDIX E: Study Drug Preparation, Dosing, Administration and Storage.....	59
	APPENDIX F: 2006 Update of ASCO Practice Guideline Recommendations for the Use of White Blood Cell Growth Factors: Guideline Summary .....	60
	APPENDIX G: Memo for dexamethasone dose reduction with concomitant administration of fosaprepitant.....	63

**Figure 1: Study Schema**

## 1 BACKGROUND

Pancreatic cancer continues to be a highly lethal disease with an overall 5 year survival of only 8%. Since 2004, the incidence of pancreatic cancer has been increasing by 1.5% per year and it is estimated that there will be 53,670 new cases diagnosed in the United States in 2017, with 43,090 expected deaths. Pancreatic cancer is the third most common cause of cancer-related deaths in both men and women, and the incidence is about equal in both sexes (Siegel 2017). Of all types of pancreatic cancers, pancreatic ductal adenocarcinoma (PDA) is by far the most common, representing 80% of cases (Dragovich 2012).

Due to lack of adequate screening techniques, greater than 80% of patients at the time of diagnosis present with unresectable, advanced disease. Standard treatment options for inoperable patients with locally advanced and metastatic PDA have been quite limited. Gemcitabine monotherapy, approved by the FDA in 1996, demonstrated a median survival of 5.7 months (Burris 1997), and has been the mainstay in treating patients with PDA. The first combination regimen to demonstrate any survival benefit compared with gemcitabine alone was gemcitabine plus erlotinib, with median survival of 6.24 months versus 5.91 months for single agent gemcitabine (Moore 2007).

A meta-analysis of randomized trials by Heinemann and colleagues showed that patients with advanced pancreatic cancer and a good performance status may benefit from combination chemotherapy with gemcitabine plus a platinum agent or a fluoropyrimidine (Heinemann 2008). Multiple combination regimens are being utilized.

Recently, the regimen of 5-fluorouracil/leucovorin/irinotecan/oxaliplatin (FOLFIRINOX) compared with gemcitabine demonstrated improvement in both progression-free survival (PFS, 6.4 vs. 3.3 months) and overall survival (OS, 11.1 vs. 6.8 months) for patients with a good performance status. FOLFIRINOX, however, is associated with substantial grade 3 and 4 toxicities, including diarrhea, nausea, vomiting, fatigue, neutropenia and febrile neutropenia, and cannot be given to patients >76 years of age or in some cases patients with head of the pancreas tumors (Conroy 2011, Assaf 2011).

An international phase III trial comparing paclitaxel protein bound (now called paclitaxel protein bound) plus gemcitabine to gemcitabine single agent demonstrated a statistically significant improvement in OS (8.5 vs. 6.7 months) for advanced pancreatic cancer patients using the gemcitabine and paclitaxel protein bound over gemcitabine alone (Von Hoff 2013).

A recently completed phase Ib/II trial of the combination of paclitaxel protein bound plus gemcitabine plus cisplatin in previously untreated stage IV pancreatic adenocarcinoma patients was presented at the 2017 Gastrointestinal Cancer Symposium (Jameson et al, 2017). In 24 patients with stage IV pancreatic cancer they reported 8.3% complete response (CR), 62.5% partial response (PR), 16.7% stable disease and 12.5% progressive disease. The rationale for adding cisplatin to paclitaxel protein bound and gemcitabine is that in a study of 1,029 patients whose pancreatic cancer tumors underwent molecular profiling, 57% of these tumors were negative for ERCC1, indicating sensitivity to a platinum anti-tumor agent (Von Hoff 2012). In addition to the above, in our whole genome/transcriptome sequencing analysis, we found that abnormal repair pathways were a feature of all of the pancreatic cancers that were sequenced (Liang 2012). Cisplatin prevents cellular DNA repair by binding to and causing crosslinking of DNA, triggering apoptosis. Cisplatin has been used in other combination regimens to treat patients with PDA. For example, the cisplatin, epirubicin, 5-fluorouracil and gemcitabine (PEFG) regimen had an acceptable toxicity profile and was associated with a 24% partial response rate, 5 month PFS and 8.3 month OS as second line therapy (Reni 2008).

Most recently, Sherman et al 2014 showed that Vitamin D can change the pancreatic tumor microenvironment from an immunologically suppressive (tumor promoting) one to an immunologically hostile one (e.g. decreased IL-6, decreased CXCL12 etc.). In addition, in the Sherman study, the vitamin D ligand calcipotriol decreased production of collagen, decreased myeloid derived suppressor cells (MDSCs) and decreased regulatory T cells. Remarkably, in clinical practice, the vitamin D analogue paricalcitol was observed to reverse chemotherapy resistance. Two individuals with pancreatic adenocarcinoma who were receiving paclitaxel protein bound and gemcitabine based combination chemotherapy developed progressive disease which was reversed by the addition of paricalcitol (unpublished SU2C data; Figure 1).

Based upon these promising clinical and pre-clinical data we are initiating a clinical trial combining paclitaxel protein bound, gemcitabine, and cisplatin for patients with metastatic PDA. When these patients develop stable or progressive disease the vitamin D analog paricalcitol will be added to the regimen. The treatment will continue until further disease progression.

## **1.1 Potential Risks of Paclitaxel Protein Bound**

The most common toxicities reported for paclitaxel protein bound include myelosuppression, predominantly neutropenia, infections (24%), dyspnea (12%), peripheral neuropathy and nausea and vomiting, myalgias and arthralgias, mucositis, alopecia, transaminitis, serum creatinine elevation. Other reported infrequent toxicities include; allergic reaction, loss of appetite, diarrhea, constipation, cough, edema, fever, pruritus, hypotension, nail changes, vision changes, rash, pulmonary edema, irregular heartbeat (see Appendix E).

## **1.2 Potential risks of cisplatin**

The most common toxicities of cisplatin include nephrotoxicity (28-36%; acute renal failure and chronic renal insufficiency), peripheral neuropathy (dose and duration dependent), nausea and vomiting (76% to 100%), myelosuppression (25% to 30%; nadir: day 18-23; recovery: by day 39; mild with moderate doses, mild-to-moderate with high-dose therapy), elevation of liver enzymes (especially SGOT and bilirubin), ototoxicity (10% to 30%; manifested as high frequency hearing loss; ototoxicity is especially pronounced in children), tissue irritation (extravasation).

Other toxicities (<1%) include alopecia (mild), anaphylactic reaction, arrhythmias, arterial vasospasm (acute), blurred vision, bradycardia, diarrhea, heart block, heart failure, hemolytic anemia (acute),

hemolytic uremic syndrome, hypercholesterolemia, hypocalcemia, hypokalemia, hypomagnesemia, hyponatremia, hypophosphatemia, limb ischemia (acute), mesenteric ischemia (acute), myocardial infarction, myocardial ischemia, mouth sores, neutropenic typhilitis, optic neuritis, orthostatic hypotension, pancreatitis, papilledema, phlebitis, reversible posterior leukoencephalopathy syndrome (RPLS), SIADH, stroke, thrombophlebitis, thrombotic thrombocytopenic purpura (see Appendix E).

### 1.3 Potential Risks of Gemcitabine

The most common toxicities reported for gemcitabine include myelosuppression, transient elevations in serum transaminases (approximately 70%), nausea and vomiting (69%), fever (41%), rash (30%), diarrhea (19%), flu syndrome, (19%), infection (16%), alopecia (15%), edema (13%), stomatitis (11%), neurotoxicity (mild 10%, severe <1%), mild proteinuria and hematuria; Hemolytic Uremia Syndrome (HUS) reported rarely (0.25%), dyspnea (0.2%) and serious pulmonary toxicity (0.06%). Also reported include constipation and pruritus (see Appendix E).

### 1.4 Rationale and Potential Risks of Paricalcitol

Paricalcitol [19-nor-1 $\alpha$ , 25 – dihydroxyvitamin D<sub>2</sub>] (also known as Zemplar) is a vitamin D analog of calcitriol with modifications to the side chain (D<sub>2</sub>) and the A (19-nor) ring. We have selected paricalcitol as our Vitamin D analog based on its broad use over a decade in the management of calcium and Vitamin D homeostasis in patients undergoing renal dialysis and because it has been used in an ongoing neoadjuvant clinical trial with albumin-bound paclitaxel + gemcitabine (NCT02030860) with good safety in the first 15 patients (personal communication with PI Dr. O'Dwyer). Paricalcitol is chemically designated as 19-nor-12, B (3), 25-trihydroxy-9, 10-secoergosta-5(Z), 7 (E), 22 (E)-triene, and is a non-metabolized vitamin D analogue that has little hypercalcemic activity (see Appendix E for package insert). As such, it is the ideal compound to effect the desired transcriptional change in the tumor microenvironment (Sherman et al, 2014). In addition to well-established effects on bone mineral homeostasis, there is increasing recognition that vitamin D may play a role in renal and cardiovascular function, as well as T cell function in some circumstances. Randomized clinical trials showed a positive effect of paricalcitol in patients with chronic renal disease on mineral metabolism, on cardiovascular outcome, and on markers of kidney damage (Bellasi et al, 2013). These positive effects have been observed not only in patients with elevated intact parathyroid hormone (iPTH), but even in those with low levels of this hormone (Cozzolino et al, 2012). The recommended starting dose of paricalcitol is 0.04 micrograms/kg (or about 3 micrograms per dose), but total weekly doses of 15 to 30 micrograms are reported in the literature without safety concerns (Kettler et al, 2012, Tonbul et al, 2012). A trial in combination with taxol in breast cancer patients gave up to 7 micrograms per day for 12 weeks (Lawrence et al, 2013).

There have been other trials of paricalcitol in cancer patients. In a population of prostate cancer patients (mean age 74) thrice weekly paricalcitol was administered at doses up to 25 micrograms, with no dose-limiting toxicity (Schwartz et al, 2005). The authors suggested that higher doses could be explored. However, we do not feel higher doses are needed in this trial, since all patients in their study showed a decline in iPTH, with minimal toxicity. There was mild nausea in 8/18 patients, mild vomiting in 2/18 patients, and a photosensitive rash in 1/18. Four patients developed hypercalcemia, only one higher than 12 mg/dl (and this only 14.3 mg/dl) (Schwartz et al, 2005). Accordingly we propose to use a three times weekly IV schedule (given concerns regarding oral absorption in pancreatic cancer patients) at a flat dose of 25 micrograms.

#### 1.4.1 Potential risks of paricalcitol

- Gastrointestinal Disorders: abdominal discomfort, constipation, diarrhea, nausea, vomiting, dysphagia, gastritis, intestinal ischemia, rectal hemorrhage, gastrointestinal hemorrhage, aspartate aminotransferase increased
- General Disorders and Administration Site Conditions: asthenia, chest discomfort, chest pain, peripheral edema, fatigue, feeling abnormal, gait disturbance, injection site extravasation, injection site pain, pain, swelling, thirst, chills, fever
- Infections and Infestations: nasopharyngitis, upper respiratory tract infection, vaginal infection, influenza, pneumonia, sepsis
- Metabolism and Nutrition Disorders: decreased appetite, hypercalcemia, hyperkalemia, hyperphosphatemia, hypocalcemia, weight decreased
- Musculoskeletal and Connective Tissue Disorders: joint stiffness, muscle twitching, myalgia, arthralgia
- Neoplasms Benign, Malignant and Unspecified: breast cancer
- Nervous System Disorders: cerebrovascular accident, dizziness, dysgeusia, headache, hypoesthesia, myoclonus, paresthesia, syncope, unresponsive to stimuli
- Psychiatric Disorders: agitation, confusional state, delirium, insomnia, nervousness, restlessness
- Reproductive System and Breast Disorders: breast pain, erectile dysfunction
- Respiratory, Thoracic and Mediastinal Disorders: cough, dyspnea, orthopnea, pulmonary edema, wheezing
- Skin and Subcutaneous Tissue Disorders: alopecia, blister, hirsutism, night sweats, rash (pruritic), pruritus, skin burning sensation, urticaria
- Vascular Disorders: hypertension, hypotension, angioedema
- Other: dry mouth

Please see full package insert (Appendix E) for details.

#### 1.5 Potential risks of paclitaxel protein bound plus Gemcitabine

The safety of paclitaxel protein bound plus gemcitabine was initially reported by Von Hoff and colleagues (Von Hoff 2011, Von Hoff 2013). The most common toxicities seen in the phase III trial were anemia, leukopenia, neutropenia, thrombocytopenia, fatigue, alopecia, sensory neuropathy and nausea.

#### 1.6 Potential risks of paclitaxel protein bound, plus Cisplatin, plus Gemcitabine

Most common drug related grade (gr) 3-4 adverse events (AEs), n = 25, are thrombocytopenia 76% (gr 3 = 36%, gr 4 = 40%) with no serious bleeding events, anemia 32% (gr 3 = 32%, gr 4 = 0%), neutropenia 24% (gr 3 = 20%, gr 4 = 4%), infection 20% (gr 3 = 16%, gr 4 = 4%), and diarrhea 16% (gr 3 = 16%, gr 4 = 0%). Grade 3 peripheral neuropathy was seen in only 1 pt (4%), no grade 4. Deaths on study include infection (1), cardiac arrest (1), and stroke (1) (Jameson et al 2017).


## 1.7 Study and Dose Rationale

A previously reported phase Ib/II open-label study evaluating the preliminary efficacy and safety of paclitaxel protein bound, cisplatin, and gemcitabine determined the MTD to be 125 mg/m<sup>2</sup>, 25 mg/m<sup>2</sup>, and 1000 mg/m<sup>2</sup> respectively on days 1 and 8 in a 21 day cycle (Jameson 2017). In the now completed study of 25 patients with 24 evaluable the response rate (complete response + partial response) was 71% in previously untreated metastatic pancreatic cancer.

The use of Paricalcitol has been previously reported in a dose escalation study for prostate cancer (Schwartz 2005) and has now been examined in 2 clinical trials for pancreatic cancer (NCT02930902, NCT02754726).

In unpublished data in two patients with progressive metastatic pancreatic cancer undergoing treatment with paclitaxel protein bound plus gemcitabine and paclitaxel protein bound plus gemcitabine plus cisplatin tumor shrinkage of 19 and 30% were seen with the addition of Paricalcitol (see Figure 1). The use of Paricalcitol will follow the prior regimens at a dose of 25 mcg IV three times weekly.

**Figure 2: The addition of the vitamin D analog paricalcitol to patients progressing on paclitaxel protein bound with gemcitabine based combination therapies resulted in disease response.**



## 1.8 Sequence of Drug Administration and Rationale

The sequence of drug administration is paclitaxel protein bound, then cisplatin, then gemcitabine. Paclitaxel protein bound is given first. Then after adequate hydration (see [Section 4.1](#)), the cisplatin is given. Gemcitabine is given last because paclitaxel protein bound decreases cytidine deaminase which potentiates gemcitabine activity (less degradation of gemcitabine by the enzyme).

Patients will be treated with the three drug chemotherapy combination alone unless upon reassessment they have stable or progressive disease (see study schema). At this point the individual will be offered the addition of Paricalcitol with another paired biopsy.

Paricalcitol will be given last as in the prior discussed studies (NCT02930902, NCT02754726).

## **2 OBJECTIVES**

### **2.1 Primary Objective**

The primary objective of this study is to determine the clinical benefit of adding Paricalcitol to the regimen of paclitaxel protein bound plus cisplatin plus gemcitabine for patients with stable or progressive metastatic PDA.

### **2.2 Secondary Objectives**

The secondary objectives of this study are to:

- Evaluate the mechanisms of disease progression of patients with metastatic PDA to paclitaxel protein bound plus cisplatin plus gemcitabine
- To assess the pharmacodynamics effect of Paricalcitol for patients with metastatic PDA
- Evaluate the safety of cisplatin plus paclitaxel protein bound plus gemcitabine plus paricalcitol.

### **2.3 Overview**

This is a phase II open-label pilot study evaluating the efficacy and safety of Paricalcitol to paclitaxel protein bound cisplatin, and gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma. An individual cycle of therapy will be defined as Days 1 and 8 every 21 days. Multiple cycles may be administered until the patient is withdrawn from therapy.

Overall response rates as well as individual categories of response (CR, PR, SD, and PD) will be determined using RECIST 1.1 (Eisenhauer 2009). Time-to-event endpoints, including PFS and OS will be assessed using the Kaplan-Meier method (Kaplan 1958). Evaluation of stable disease at 9 weeks will also be assessed. Toxicity (adverse events) will be recorded using the NCI CTCAE, version 4.0 (published 28 May 2009) (see Appendix D).

### **2.4 Primary Endpoints**

- To evaluate the response after the administration of Paricalcitol to those with PDA who have progressed on paclitaxel protein bound plus cisplatin plus gemcitabine by using RECIST 1.1.

### **2.5 Secondary Endpoints**

- To evaluate the pharmacodynamics effect of Paricalcitol on PDA a core biopsy will be performed at baseline prior to the addition of paricalcitol along with one after 2 cycles of the triplet regimen plus paricalcitol (6 weeks).
- To evaluate the treatment-related toxicities in this patient population.
- To evaluate the change in CA 19-9 (or CA 125, or CEA if not expressers of CA 19-9) in this patient population.
- To evaluate changes in circulating biomarkers induced by chemotherapy and paricalcitol



- To evaluate the change in parathyroid hormone (PTH) in individuals treated with paricalcitol
- To monitor and measure the serum levels of Vitamin D 25-OH with every 3 cycles of therapy

### **3 STUDY POPULATION**

#### **3.1 Patient Selection and Study Duration**

Up to 14 patients will be recruited from up to 5 study centers in the United States and the United Kingdom. Patients with stage IV metastatic pancreas ductal adenocarcinoma who have not received treatment previously will be enrolled. The expected duration of this study is 18 months. Enrollment into the screening or treatment phase of the study will be stopped when the anticipated or accrual is complete.

#### **3.2 Inclusion Criteria**

Patients must meet the following criteria to be included in the study:

1. Age  $\geq 18$  years of age; male or female.
2. Histologically or cytologically confirmed metastatic pancreatic ductal adenocarcinoma.
3. Capable of providing informed consent and complying with trial procedures including obtaining paired biopsies during therapy
4. Karnofsky Performance Status (KPS) of  $\geq 70\%$ .
5. Life expectancy  $\geq 12$  weeks.
6. Measurable tumor lesions according to RECIST 1.1 criteria.
7. Women must agree not to become pregnant (e.g. post-menopausal for at least 1 year, surgically sterile, or practicing adequate birth control methods) for the duration of the study and until 90 days after last dose of study treatment. Women of child bearing potential must have a negative serum or urine pregnancy test at the Screening Visit and be non-lactating. Both male and female patients of reproductive potential must agree to use a reliable method of birth control during the study.

#### **3.3 Exclusion Criteria**

Patients meeting the following criteria will not be enrolled:

1. Patients must have received no previous radiotherapy, surgery, chemotherapy or investigational therapy for the treatment of metastatic disease. Prior treatments in the adjuvant setting with gemcitabine and/or 5-FU or gemcitabine administered as a radiation sensitizer are allowed, provided at least 6 months have elapsed since completion of the last dose and no lingering toxicities are present.
2. Palliative surgery and/or radiation treatment less than 4 weeks prior to initiation of study treatment.
3. Exposure to any investigational agent within 4 weeks prior to initiation of study treatment.
4. Evidence of central nervous system (CNS) metastasis (negative imaging study, if clinically indicated, within 4 weeks of Screening Visit).
5. History of other malignancies (except cured basal or squamous cell carcinoma, superficial bladder cancer, prostate cancer in active surveillance, or carcinoma in situ of the cervix) unless documented free of cancer for  $\geq 2$  years.

6. Laboratory values: Screening serum creatinine  $>1.5$  mg/dL; total bilirubin  $> 1.25$  (ULN); alanine aminotransferase (ALT) and AST  $\geq 2.5$  ULN or  $\geq 5.0 \times$ ULN if liver metastases are present; absolute neutrophil count  $<1,500/\text{mm}^3$ , platelet concentration  $<100,000/\text{mm}^3$ , hematocrit level  $<27\%$  for females or  $<30\%$  for males, or coagulation tests (prothrombin time [PT], partial thromboplastin time [PTT], International Normalized Ratio [INR])  $>1.5 \times$ ULN unless on anticoagulation agents.
7. Current, serious, clinically significant cardiac arrhythmias as determined by the investigator.
8. History of HIV infection.
9. Active, clinically significant serious infection requiring treatment with antibiotics, antivirals or anti-fungals.
10. Any condition that might interfere with the patient's participation in the study or in the evaluation of the study results.

### 3.4 Patient Enrollment

This is an open-label study. A patient ID number will be assigned by the site when the patient signs the Informed Consent Form. A copy of the signed informed consent will be required for study entry.

The exact date and time of each administration of medications will be recorded in the case report form (CRF). Paricalcitol, cisplatin, paclitaxel protein bound and gemcitabine will be administered according to the clinical study protocol only to patients who have given written informed consent. Patients withdrawn from the study will retain their patient ID number. New patients must always be allotted a new patient ID number.

### 3.5 Patient Discontinuation

Patients will be discontinued from the treatment under the following circumstances:

- Disease progression after addition of paricalcitol.
- Patient's physician considers a change of therapy would be in the best interest of the patient.
- Patient requests discontinuation.
- Continued unacceptable toxicities despite optimal treatment or dose reduction.
- Patient becomes pregnant or fails to use adequate birth control (for those patients who are fertile).
- Need for any treatment not allowed by the protocol.
- Non-compliance.

### 3.6 Study Discontinuation

The investigator or sponsor has the right to terminate the participation of either an individual site or the study at any time. Reasons for terminating the study include, but are not limited to, the following:

- Incidence or severity of AEs in this or other studies indicates a potential health hazard to patients.
- Patient enrollment is unsatisfactory.
- Investigator does not adhere to the protocol or applicable regulatory guidelines in conducting the study.

## 4 STUDY TREATMENT

### 4.1 Administration and Dosing

Treatment must be administered in a hospital, clinic or other out-patient setting appropriate for chemotherapeutic infusions. No investigational or commercial agents or therapies other than those described may be administered with the intent to treat the patient's malignancy.

The solution for infusion will be prepared at each investigational site. Detailed guidelines for the preparation and administration of paclitaxel protein bound, cisplatin and gemcitabine are provided in Appendix E. The order of infusion with premedication is as follows:

- Pre cisplatin hydration: 0.9% Sodium Chloride Injection 1000 mL with 0.9% sodium chloride and Magnesium Sulfate 2 grams IV infusion over 2 hours on days 1 and 8 repeated every 21 days.
- Aloxi (palonosetron) 0.25mg IV, Emend (fosaprepitant) 150 mg IV and dexamethasone 20mg IV within 30 minutes prior to treatment on days 1 and 8, repeated every 21 days. Patients will continue oral antiemetic prophylaxis at home with ondansetron 8mg bid and dexamethasone 4mg bid for 2 days after chemotherapy.
- Paclitaxel protein bound 125mg/m<sup>2</sup> over 30 minute IV infusion on days 1 and 8 repeated every 21 days, followed by:
- Cisplatin 25mg/m<sup>2</sup> in 500 mL of NS over 60 minute IV infusion on days 1 and 8 repeated every 21 days, followed by:
- Gemcitabine 1000mg/m<sup>2</sup> in 250 ml over 30 minute IV infusion on days 1 and 8 repeated every 21 days
- Post cisplatin hydration: 0.9% Sodium Chloride Injection 500 mL IV infusion over 3 hours on days 1 and 8 repeated every 21 days. May start at the same time as the gemcitabine infusion.

Upon stable or progressive disease, paricalcitol will be given at a dose of 25 micrograms on days 1,3,5 and 8,10,12 and repeated every 21 days.

In the event of extravasation during the infusion of paclitaxel protein bound, cisplatin and gemcitabine, the infusion should be immediately terminated and patients treated according to local site protocols. The infusion should then be restarted in another vein. Paricalcitol is preferably given through central venous access.

### 4.2 Body Surface Area Calculation

The calculation of the dose of cisplatin, gemcitabine, and paclitaxel protein bound will be based on the patient's body surface area (BSA) using the Mosteller formula (Verbraeken 2006). The BSA will be calculated before each cycle, based on the actual height and weight of the patient. If there has been a > 10% weight change from Cycle 1 Day 1, the calculated dose will be adjusted downward to the nearest whole milligram.

The dose of Paricalcitol is given at a fixed dose of 25 mcg.

### 4.3 Dose Modification for Toxicity

Toxicities will be graded using the NCI CTCAE v4.0 (see Appendix D). If toxicity occurs during or after any treatment cycle, the toxicity will be graded and appropriate supportive care treatment may be administered to decrease the signs and symptoms (e.g. antiemetics, antidiarrheals, antipyretics, antihistamines).

Doses of paclitaxel protein bound and gemcitabine may be reduced in individual patients in accordance with the schedule in Table 1. In general, doses that have been reduced for toxicity will not be escalated back to the starting level. Growth factors may be used to treat hematologic toxicity and will not constitute a dose reduction.

A maximum of a 3-week treatment delay is permitted to allow recovery of toxicities.

Upon disease stable or progressive disease, paricalcitol will be given on days 1,3,5, 8, 10, and 12 at a fixed dose of 25 mcg IV. Paricalcitol will be held if there is a grade 3 or greater event attributed to paricalcitol or at the discretion of the principal investigator.

Table 1 Dose Reduction Schema

Dose Level	Paclitaxel protein bound (mg/m <sup>2</sup> )	Cisplatin Dose 1	Gemcitabine (mg/m <sup>2</sup> )
Level - 0 (baseline)	125mg/m <sup>2</sup>	No change	1000mg/m <sup>2</sup>
Level -1	100mg/m <sup>2</sup>	No change	800mg/m <sup>2</sup>
Level -2	75mg/m <sup>2</sup>	No change	600mg/m <sup>2</sup>

#### 4.3.1 Hematological Toxicity

In the event dose modifications are required at the beginning of a cycle or within a cycle due to hematologic toxicities, doses of paclitaxel protein bound, cisplatin, and gemcitabine may be adjusted as detailed in Table 2 and Table 3.

##### 4.3.1.1 Dose Modifications at Day 1

Table 2 Dose Modifications for Day 1 of Each Cycle (Hematologic Toxicity)

ANC		Platelets	Timing
$\geq 1.5 \times 10^9/L$	And	$\geq 100 \times 10^9/L$	Treat on time
$< 1.5 \times 10^9/L$	Or	$< 100 \times 10^9/L$	Delay by 1 week intervals until recovery

##### 4.3.1.2 Dose Adjustments within a Treatment Cycle

In the event that patients must have treatment delayed within a treatment cycle due to hematologic toxicities, those doses held during a cycle will not be made up. Dose modifications due to hematologic

toxicity (as represented by the blood counts and toxicities, below) within a treatment cycle should be adjusted as outlined in Table 3.

Table 3 Dose Modification for Day 8 of Each Cycle (Hematologic Toxicity)\*

Day 8 Laboratory Results	Day 8 Album-bound paclitaxel	Day 8 Cisplatin	Day 8 Gemcitabine
ANC > 1000 and Platelets $\geq$ 75,000	100%	100%	100%
ANC 500-1000 <sup>a</sup> or Platelets 50,000-74,999	Decrease dose by 1 level (treat on time)	100%	Decrease dose by 1 level (treat on time)
ANC < 500 or Platelets < 50,000	Hold	Hold	Hold
Febrile Neutropenia (Grade 3 or 4) <sup>b</sup>	Hold. Upon resuming dosing, decrease to next lower dose level and do not re-escalate throughout the rest of treatment	Hold	Hold. Upon resuming dosing, decrease to next lower dose level and do not re-escalate throughout the rest of treatment
Recurrent Febrile Neutropenia (Grade 3 or 4) <sup>b</sup>	Hold. Upon resuming dosing, decrease 2 dose levels (to 75 mg/m <sup>2</sup> ) and do not re-escalate throughout the rest of treatment	Hold	Hold. Upon resuming dosing, decrease 2 dose levels (to 600 mg/m <sup>2</sup> ) and do not re-escalate throughout the rest of treatment.

\* see Table 1 for dose reduction schedule a If patients do not experience resolution of neutropenia within 21 days, despite uninterrupted G-CSF treatment, study treatment will be discontinued. b Febrile patients (regardless of neutrophil count) should have their chemotherapy treatment interrupted. A full sepsis diagnostic work-up should be performed while continuing broad spectrum antibiotics. If cultures are positive, the antibiotic may or may not be changed, depending on the sensitivity profile of the isolated organism. Patients with persisting fever after 3 weeks, despite uninterrupted antibiotic treatment, will discontinue study treatment. Febrile neutropenic patients can also receive G-CSF, in addition to antibiotic treatment, to hasten the resolution of their febrile neutropenia (following current institutional guidelines). In all cases, blood counts must have returned to baseline levels before resuming chemotherapy treatment.

#### 4.3.2 Non-hematological Toxicity

Dose reductions for non-hematologic toxicity that occur despite adequate background medical therapy should be undertaken in accordance with Table 4. Cisplatin is addressed in sections 4.3.2.1, 4.3.2.2, and 4.3.2.7.

Table 4. Paclitaxel protein bound and gemcitabine and cisplatin Dose Modifications for Day 1 of Each Cycle (Non-hematologic Toxicity)\*

Non Hematologic Toxicity and/or Dose Hold with Previous Cycle	
Toxicity/dose held	<i>paclitaxel protein bound + gemcitabine dose this cycle</i>
Grade 0, 1 or 2 toxicity	Same as Day 1 previous cycle (except for Grade 2 cutaneous toxicity where doses of paclitaxel protein bound and gemcitabine should be reduced to next lower dose level: please refer to <a href="#">Section 4.3.2.3</a> )
Grade 3 toxicity <sup>a,c</sup>	Decrease <i>paclitaxel protein bound</i> and gemcitabine to next lower dose level <sup>a</sup>
Grade 4 toxicity <sup>b</sup>	Off protocol treatment <sup>b</sup>
Dose held in 2 previous consecutive cycles	Decrease paclitaxel protein bound and gemcitabine to next lower dose level and continue throughout the rest of treatment

\* Excluding peripheral neuropathy (section 4.3.2.1) and nephrotoxicity (section 4.3.2.2).

<sup>a</sup> If the toxicity only affects neuropathy, then only paclitaxel protein bound should be reduced (please see Section 4.3.2.1).

<sup>b</sup> Pulmonary embolism (a Grade 4 toxicity in the CTCAE tables) if mild or asymptomatic, will be exempt from this requirement (please see Section 4.3.2.5).

<sup>c</sup> Excluding electrolyte abnormalities per judgment of the physician/investigator.

Table 5. Paclitaxel protein bound and gemcitabine and cisplatin Dose Modifications Day 8 Each Cycle (Non-hematological Toxicity)

CTC Grade	Percent of Day 1 <i>paclitaxel protein bound + gemcitabine Dose</i>
0-2	100% <sup>a</sup>
3+	Hold treatment until resolution to ≤ Grade 1 <sup>b,c</sup> .

<sup>a</sup> Except for cutaneous toxicity: please refer to [Section 4.3.2.3](#). <sup>b</sup> Pulmonary embolism (a Grade 4 toxicity in the CTCAE tables) if mild or asymptomatic, will be exempt from this requirement (please see [Section 4.3.2.5](#)).

<sup>c</sup> Excluding electrolyte abnormalities per judgment of the physician/investigator.

#### 4.3.2.1 Peripheral Neuropathy

Cisplatin and paclitaxel protein bound treatment should be withheld in patients who experience ≥ Grade 3 peripheral neuropathy. Gemcitabine administration can continue during this period. Cisplatin may be resumed at the same dose and paclitaxel protein bound treatment may be resumed at the next lower dose level in subsequent cycles after the peripheral neuropathy improves to ≤ Grade 1. Patients experiencing peripheral neuropathy that requires a delay in scheduled cisplatin and paclitaxel protein bound dosing for ≥ 21 days will discontinue study treatment. The time to resolution to Grade ≤ 1 should be the adverse event duration used for adverse event reporting.

#### 4.3.2.2 Nephrotoxicity

Cisplatin (cisplatin injection) produces cumulative nephrotoxicity which is potentiated by aminoglycoside antibiotics (see Appendix E). The [serum creatinine](#), BUN, creatinine clearance, and [magnesium](#), [sodium](#), [potassium](#), and [calcium](#) levels should be measured prior to initiating [therapy](#), and prior to each subsequent course. Cisplatin should not be given unless serum creatinine is ≤ 1.5 mg/dl.

#### 4.3.2.3 Cutaneous Toxicity

Patients who develop Grade 3 cutaneous toxicity should have their dose reduced to the next lower dose level as per Table 1. If the patient continues to experience these reactions, despite dose reduction, treatment should be discontinued. Patients who develop Grade 4 cutaneous toxicity should have treatment discontinued.

#### 4.3.2.4 Gastrointestinal Toxicity

If Grade 3 mucositis or diarrhea occurs, all 3 (or 4 if on paricalcitol) study drugs should be withheld until resolution to  $\leq$  Grade 1, then reinstituted at the next lower dose level as per Table 1. Patients who

#### 4.3.2.5 Pulmonary Embolism

Asymptomatic or clinically mild pulmonary embolism can be treated with low-molecular weight heparin without interruption of therapy. Moderate to severe pulmonary embolism will require permanent discontinuation of treatment.

#### 4.3.2.6 Interstitial Pneumonitis

Pulmonary toxicity has been reported for both gemcitabine and paclitaxel. Epidemiology reports show that gemcitabine monotherapy is weakly associated with lung toxicity. A retrospective review (Meadors 2006) of pooled clinical trial data of 4,448 patients with mixed cancer indications reported an incidence of dyspnea of 0.2% and serious pulmonary toxicity of 0.06%.

Paclitaxel monotherapy is weakly associated with lung toxicity (Rowinsky 1995). Dyspnea with bronchospasm has been reported in 0.3 to 0.9%, with 30% of type 1 hypersensitivity reactions. Combination chemotherapy of gemcitabine and paclitaxel shows a higher incidence of this complication compared to either drug alone.

During study participation, patients should be carefully monitored for signs and symptoms of pneumonitis (i.e. episodes of transient or repeated dyspnea with unproductive persistent cough or fever) and, if observed, immediate clinical evaluation and timely institution of appropriate management (emphasizing the need for corticosteroids if an infectious process has been ruled out as well as appropriate ventilation and oxygen support when required). Administration of study drugs will be permanently discontinued upon making a diagnosis of interstitial pneumonitis.

##### 4.3.2.6.1.1 Prevention, Surveillance and Management of Interstitial Pneumonitis

During study treatment, episodes of transient or repeated dyspnea with unproductive persistent cough or fever should be paid attention to. Radiographic evaluation with chest X-rays and CT scans (normal or high resolution) may be indicated to look for infiltrates, ground-glass opacities or honeycombing patterns. Pulse oximetry and pulmonary function tests can show respiratory and ventilation compromise.

Infections should be ruled out with routine immunological/ microbiological methods. Transbronchial lung biopsy is not recommended, given its limited value and risk of pneumothorax and hemorrhage, and should be reserved for cases with unclear etiology.

Study drug administration should be interrupted upon diagnosis of interstitial pneumonitis and patients permanently discontinued from further study drug treatment. After ruling out an infectious etiology, intravenous high-dose corticosteroid therapy and secondary pathogen coverage should be instituted without delay. Patients with an added immunological component may also require immune modulation with azathioprine or cyclophosphamide. Appropriate ventilation and oxygen support should be used when required.

#### 4.3.2.7 Hypersensitivity Reactions

Hypersensitivity reactions are not usually expected with cisplatin, paclitaxel protein bound or gemcitabine. If they do occur, minor symptoms such as flushing, skin reactions, dyspnea, hypotension, or tachycardia may require temporary interruption of the infusion. However, severe reactions, such as hypotension requiring treatment, dyspnea requiring bronchodilators, angioedema, or generalized urticaria require immediate discontinuation of the offending agent and aggressive symptomatic therapy. Patients who develop a severe hypersensitivity reaction should not be rechallenged.

#### 4.3.2.8 Colony Stimulating Factors

Based on the ASCO guidelines (Smith 2006) for use of granulocyte colony stimulating factors, (G-CSF) for regimens with at least a 20% risk of febrile neutropenia, pegfilgrastim will be administered subcutaneously on day 9 of each treatment cycle. G-CSF may also be given according to institutional guidelines for the treatment of neutropenic fever or infections associated with neutropenia and for the prevention of febrile neutropenia in patients with an ANC < 500 cells/ $\mu$ L (see [Appendix F](#)). Patients not experiencing resolution of neutropenia within 21 days, despite uninterrupted G-CSF treatment, will discontinue study treatment.

#### 4.3.2.9 Prophylaxis against Sepsis

Due to the incidences of non-neutropenic sepsis, at the first occurrence of fever  $\geq 38.5^{\circ}\text{C}$  (regardless of neutrophil count), institution of ciprofloxacin (500 mg orally, twice daily)—or amoxicillin/clavulanate (Augmentin<sup>®</sup>, 500 mg orally, 2-3 times daily) in patients with allergy to fluoroquinolones—should be initiated. On their first visit, patients should be provided with enough ciprofloxacin (or the alternative antibiotic) for use at home, and they should be instructed to begin taking it when they first record a temperature of  $\geq 38.5^{\circ}\text{C}$  (or if they feel they are developing a fever and a thermometer is not available). They should also immediately contact their physician for guidance on where to go for blood counts and to be evaluated for sepsis as soon as possible. Hospitalization or evaluation in the emergency room may be required depending on the clinical presentation. If hospitalization is required, please refer to [Section 7.7](#) of this protocol to report the event as a Serious Adverse Event (SAE).

#### 4.3.2.10 Hypercalcemia

Upon stable or progressive disease of therapy with paclitaxel protein bound, cisplatin, and gemcitabine and the initiation of paricalcitol extra care must be given to monitored for vitamin D intoxication and hypercalcemia. Serum calcium and phosphorus levels should be checked at least weekly. Serum or plasma intact PTH (iPTH) should be checked at least every 3 weeks. If signs and symptoms of vitamin D intoxication and hypercalcemia occur, paricalcitol must be held. For further information refer to the package insert ([Appendix E](#)).

### 4.4 Intended Dose Delays

Intended cycles may be delayed for non-toxicity reasons for up to 14 days (for reasons such as scheduling conflicts or adverse events), but only with documentation and explanation in the CRF.

### 4.5 Concomitant Therapy

Necessary supportive measures for optimal medical care may be given throughout the study, including IV antibiotics to treat infections, blood components, and antiemetics. Additional care will be administered as indicated by the treating physician and the patient's medical need. No concomitant cytotoxic therapy, whether conventional or investigational, will be allowed during this study. All concomitant medications and supportive therapy must be recorded on the appropriate CRF.



Radiotherapy is not allowed while the patient is enrolled in this study.

Routine **prophylactic use** of a colony-stimulating factor (G-CSF) should be used according to the American Society of Clinical Oncology guidelines ([Appendix F](#)).

Erythropoietin is permitted if clinically indicated.

The use of medical marijuana (except FDA-approved therapy) in any formulation should be avoided while enrolled in this study.

The use of additional vitamin D supplements while receiving study-administered paricalcitol should be avoided unless the patient is vitamin D deficient.

## 4.6 Concomitant Therapies Requiring Caution

Cisplatin nephrotoxicity may be exacerbated by treatment with other nephrotoxic drugs (e.g. aminoglycoside antibiotics, non-steroidal anti-inflammatory drugs). Caution with use of other nephrotoxic drugs.

If anticoagulation with warfarin is necessary, frequent monitoring of prothrombin time and the International Normalized Ratio (INR) is recommended. Please see Appendix G for special precautions on the use of dexamethasone with concomitant fosaprepitant.

# 5 STUDY ASSESSMENTS

## 5.1 Laboratory Assessments

All hematology, blood chemistries, urinalyses, and serum or urine pregnancy tests (if applicable) will be performed by the local laboratory for each investigational site.

Prior to study enrollment, each patient will have the following assessments (see Appendix A).

## 5.2 Screening (Within 21 Days Prior to First Dose)

- Written informed consent
- Medical history including concurrent baseline conditions (using NCI CTCAE version 4.0; Appendix D), prior cancer therapy (including documentation of prior surgery, adjuvant or neoadjuvant chemotherapy and radiotherapy)
- Inclusion/exclusion review
- Complete physical examination including height (cm) and weight (kg)
- Karnofsky Performance Status (KPS) (see Appendix B).
- Vital signs including blood pressure, pulse, respiratory rate, and temperature
- Computed tomography (CT) / magnetic resonance imaging (MRI) scan to document disease status (including chest, abdomen, pelvis, and other regions as clinically indicated. In addition, brain scan is required to exclude brain metastases if clinically indicated only.). If a CT scan was taken within 28 days prior to first dose, a new scan is not necessary (see RECIST 1.1 criteria in Section 6)

- Electrocardiogram (ECG)
- Complete blood count (CBC) with differential and platelet count
- Serum chemistries (for hepatic and renal function tests) including: blood urea nitrogen (BUN), phosphorus, magnesium, creatinine, creatinine clearance, total protein, albumin, calcium, glucose, total bilirubin, alkaline phosphatase (ALP), aspartate aminotransferase (AST), alanine aminotransferase (ALT), PT/INR/PTT, electrolytes (chloride, sodium, potassium, and bicarbonate)
- Vitamin D 25-OH
- Parathyroid Hormone
- CA 19-9 (or CA 125, or CEA if not expressers of CA 19-9)
- Urinalysis including protein, specific gravity, glucose, and blood
- Fecal swab
- Serum pregnancy test (if applicable)
- Concomitant medication notation (to include all medications taken within 30 days prior to study enrollment)
- Archived tumor tissue, if available, will be obtained for further profiling work.

Once eligibility is confirmed, site personnel should assign a patient ID number.

### 5.3 On-Study Assessments

Patients must begin Cycle 1 within 21 days of signing the informed consent document and after the screening assessments. Treatment will be administered by qualified and trained site personnel in a hospital, clinic, or other out-patient setting appropriate for chemotherapeutic infusions. All assessments should be performed within 72 hours of each specified time parameter, with the exception of Cycle 1 and subsequent D1 in each cycle in which assessments must be conducted within 48 hours (except those noted), or if medical or scheduling conditions require a delay.

#### Day 1 of each cycle (except where noted) (+/- 48 hours)

- Inclusion/exclusion review (Cycle 1 only)
- Directed physical exam
- Vital Signs including blood pressure, pulse, respiratory rate, and temperature
- Measurement of weight (kg)
- BSA calculation prior to dosing (After Cycle 1, the BSA only needs to be changed if there has been a change >10% in body weight from Cycle 1-Day 1 (See Section 4.2)).
- Karnofsky Performance Status (KPS) (see Appendix B)
- Hematology: CBC with differential and platelet count
- Serum chemistries (for hepatic and renal function tests) including: blood urea nitrogen (BUN), phosphorus, magnesium, creatinine, creatinine clearance, total protein, albumin, calcium, glucose, total bilirubin, alkaline phosphatase (ALP), aspartate aminotransferase (AST), alanine aminotransferase (ALT), parathyroid hormone (PTH) and electrolytes (chloride, sodium, potassium, and bicarbonate).
- CA 19-9 (or CA 125, or CEA if not expressers of CA 19-9)
- Vitamin D 25-OH
- Urinalysis including protein, specific gravity, glucose, and blood

- Fecal swab
- Serum pregnancy test (if applicable)
- AEs using the NCI CTCAE (see Appendix D)
- Concomitant medication
- Blood sample for research. For further details please refer to the accompanying lab manual.
- Study treatment regimen as described in the previous section.

#### Day 8 of each cycle

- Directed physical exam as clinically indicated
- Vital Signs including blood pressure, pulse, respiratory rate, and temperature
- Measurement of weight (kg)
- Karnofsky Performance Status (KPS) (see Appendix B)
- Hematology: CBC with differential and platelet count
- Serum chemistries (for hepatic and renal function tests) including: blood urea nitrogen (BUN), phosphorus, magnesium, creatinine, creatinine clearance, total protein, albumin, calcium, glucose, total bilirubin, alkaline phosphatase (ALP), aspartate aminotransferase (AST), alanine aminotransferase (ALT), and electrolytes (chloride, sodium, potassium, and bicarbonate).
- AEs using the NCI CTCAE (see Appendix D)
- Concomitant medication notation
- Study treatment regimen as described in the previous section.

#### Day 15 of each cycle

- Directed physical exam
- Vital Signs including blood pressure, pulse, respiratory rate, and temperature
- Karnofsky Performance Status (KPS) (see Appendix B)
- Hematology: CBC with differential and platelet count
- Serum chemistries (for hepatic and renal function tests) including: blood urea nitrogen (BUN), phosphorus, magnesium, creatinine, creatinine clearance, total protein, albumin, calcium, glucose, total bilirubin, alkaline phosphatase (ALP), aspartate aminotransferase (AST), alanine aminotransferase (ALT), parathyroid hormone (PTH) and electrolytes (chloride, sodium, potassium, and bicarbonate).
- AEs using the NCI CTCAE (see Appendix D)
- Concomitant medication notation

#### Days 3, 5, 10 and 12 of each cycle (after initiation of Paricalcitol treatment)

- Vital Signs including blood pressure, pulse, respiratory rate, and temperature
- AEs using the NCI CTCAE (see Appendix D)
- Concomitant medication notation
- Study treatment regimen as described in the previous section.

#### Prior to Cycles 3 or later (after initiation of Paricalcitol treatment and 6 weeks later (+/- 1 week))

The patient will have a biopsy of their tumor upon stable or progression of disease in response to paclitaxel protein bound, gemcitabine, and cisplatin therapy (and as a possible helpful piece of information based on profiling that will be done on that biopsy). This will be done prior to the introduction of paricalcitol.

The tumor will be tested for various biomarkers as outlined below, although it may not be feasible to test for all. (please see lab manual for further details):

- Stromal content (collagen and hyaluronan).
- CD31 staining.
- PD-1/ PDI-1 staining and expression.
- IHC evaluation of key immune cell populations (cytotoxic T Cells, TAMs, MDSCs, and Tregs).
- Clonality of intratumoral T cells by TSR sequencing (a measure of intratumoral response)
- Expression of VDR regulated inflammatory gene (IL6, CXCL1, CSF2, CXCLR).
- VDR and CYP24A1.
- Mutational and transcriptional profile.

Additional analysis may be done if tissue is available. For further details please refer to the accompanying lab manual.

#### Repeat Biopsy

A repeat biopsy will be performed (protocol condition permitting) at 6 ±1 weeks of therapy after the addition of paricalcitol. The same studies will be performed as was performed on the original biopsy refer to section 5.3 and the accompanying lab manual.

After Cycle 3, 6, 9 a CT/MRI scan to evaluate disease status using same imaging method as Baseline will be completed at the end of the cycle prior to starting the next cycle.

Note: In order to more precisely determine time to progression, the investigator is encouraged to obtain radiological assessments and CA19-9 values earlier if there is a strong clinical suspicion of disease progression. In order to either confirm or refute the clinical impression.

## **5.4 End of Treatment**

When the patient completes all cycles of study medication, or withdraws from treatment prior to completing all cycles, the following assessments will be performed 14-28 (+/- 2) days after completing the last dose of study medication:

- Directed physical exam
- Vital Signs including blood pressure, pulse, respiratory rate, and temperature
- Measurement of weight (kg)
- Karnofsky Performance Status (KPS) (see Appendix B)
- Hematology: CBC with differential and platelet count
- Serum chemistries (for hepatic and renal function tests) including: blood urea nitrogen (BUN), phosphorus, magnesium, creatinine, creatinine clearance, total protein, albumin, calcium, glucose, total bilirubin, alkaline phosphatase (ALP), aspartate aminotransferase (AST), alanine aminotransferase (ALT), parathyroid hormone (PTH) and electrolytes (chloride, sodium, potassium, and bicarbonate).

- CA 19-9 (or CA 125, or CEA if not expressers of CA 19-9)
- Fecal swab
- Urinalysis including protein, specific gravity, glucose, and blood
- Serum pregnancy test (if applicable)
- AEs using the NCI CTCAE (see Appendix D)
- Concomitant medication

## **5.5 Follow-Up Assessments after End of Study or Early Termination**

Follow up assessments by telephone will be conducted for all patients or their families every 12 weeks after the last dose of study treatment to determine the date of death.

## **5.6 Statistical Considerations**

The sample size of this pilot study will be up to 14 patients.

Time-to-event endpoints, including PFS and OS will be assessed using the Kaplan-Meier method (Kaplan 1958).

Objective response rates, clinical benefit response, and CA 19-9, will be summarized descriptively.

## **5.7 Treatment Assignment**

This is a phase 2 open-label pilot trial, with the identity of the treatment known to the patients, Investigators, and Sponsor.

## **5.8 Patient Disposition**

A detailed description of patient disposition will include:

- A summary of data on patient discontinuation from treatment.
- A summary of data on overall qualification status of all patients.
- An account of all identified protocol deviations.
- All patients enrolled in the study will be included in the summation. An evaluable patient is any patient who has received even one dose of drug. The number of patients who do not qualify for analysis, who die or discontinue before treatment begins, will be specified.

## **5.9 Patient Characteristics**

Patient characteristics will include a summary of the following:

- Patient demographics
- Baseline disease characteristics
- Pre-existing conditions
- Prior therapies
- Concomitant medications and treatments
- Other patient characteristics will be summarized as appropriate.

## 5.10 Efficacy Analysis

The efficacy analysis will include the following parameters: objective response rate (CR + PR), disease control rate (CR + PR + SD at 9 weeks), PFS, stable disease rate at 9 weeks (SD), and OS. The efficacy analysis will only be conducted on patients who have received at least one dose of cisplatin, paclitaxel protein bound and gemcitabine and have at least one tumor assessment. Further efficacy analysis will be conducted upon the progression of disease on paclitaxel protein bound and gemcitabine and cisplatin and the addition of paricalcitol.

Objective responses will be evaluated using the Response Evaluation Criteria In Solid Tumors 1.1 (RECIST 1.1). Changes (i.e. improvements) in tumor measurements from baseline values will be assigned a status of CR or PR or SD. Objective response measurements will comprise the sum of CR plus PR. The overall response rate, as well as the rates for the individual categories of response (i.e. CR, PR, SD, and PD), will be estimated by the percentage of patients achieving these criteria. The disease control rate will consist of the sum of CR + PR + SD for 9 weeks.

Progression-free survival is defined as the interval from the date of the addition of paricalcitol upon progression of paclitaxel protein bound and gemcitabine and cisplatin to the earliest date of documented evidence of recurrent or progressive disease, or the date of death due to any cause, whichever occurs first. For the estimation of progression-free and overall survival a Kaplan-Meier analysis will be performed.

Overall survival will be measured from the date of registration (i.e. assignment of patient number) to the date of death due to any cause, or the date of last contact (censored observations). Overall survival will also be measured from the time of disease progression on paclitaxel protein bound and gemcitabine and cisplatin and those who then undergo therapy with paricalcitol.

## 5.11 Safety Analysis

All patients who receive any amount of cisplatin, paclitaxel protein bound and gemcitabine will be included in the safety analyses, which will include the following:

- The incidence, severity, duration, causality, seriousness, and type of AEs and changes in the patient's physical examination, vital signs, and clinical laboratory results.
- In addition, deaths and other SAEs will be tabulated.
- Use of concomitant medications.

## 5.12 Replacement of Patients

Patients who are enrolled into the study, but fail to receive paclitaxel protein bound, cisplatin, and gemcitabine may be replaced.

## 5.13 Quality Assurance

The study will be initiated and conducted under HonorHealth. Representatives of HonorHealth will monitor the study to verify study data, medical records, and CRFs in accordance with current ICH GCP guidelines as well as other applicable regulations and guidelines.

## 5.14 Chain of Custody of Biological Samples

In all cases, patients will be consented for the collection and use of their biological samples and a full chain of custody will be maintained for all samples throughout their lifecycle. The Investigator at each site is responsible for maintaining a record of full traceability of biological samples collected from patients while these are in storage at the site, either until shipment or disposal. Any sample receiver e.g. sub-contracted service provider will keep full traceability of samples from receipt of arrival to further shipment or disposal (as appropriate).

In the event that a patient withdraws their consent from the study, all samples and data collected up to that date will be used in the study but no further data will be collected. HONORHEALTH will keep overall oversight of the entire lifecycle through internal procedures and monitoring of study sites, the Study Tissue Access Committee will be the custodian of the samples. Samples will be transferred from UK sites to the Barts Pancreas Tissue Bank (REC Ref: 13/SC/0592, HTA Licensing number: 12199) and from USA sites to the TGen Tissue Repository (TGen Protocol # mdemeure12-034). Those retained for further ethically approved research will be registered with the Barts Pancreas Tissue Bank (REC Ref: 13/SC/0592, HTA Licensing number: 12199) and / or the TGen Tissue Repository (TGen Protocol # mdemeure12-034). Samples may be transferred to organisations (including commercial organisations) outside the USA or EU for analysis.

## **6 EVALUATION OF RESPONSE**

### **6.1 Best Overall Response**

Best overall response is defined as the best response recorded from the start of the treatment until disease progression/recurrence (taking as reference for tumor progression, the smallest measurements recorded since the treatment started). The patient's best response assignment will depend on the achievement of both measurement and confirmation criteria.

### **6.2 Overall Tumor Response**

The overall tumor response rate is defined as the total proportion of patients who have an objective tumor response (CR + PR). Rates for the individual categories of response (CR, PR, SD, and PD) will also be determined.

### **6.3 Not Evaluable**

Patients will be defined as being not evaluable for response if a radiological assessment cannot be made. These patients will be counted as treatment failures in the analysis of tumor response data.

In some circumstances, it may be difficult to distinguish residual disease from normal tissue. When the evaluation of a CR depends upon this determination, it is recommended that the residual lesion be investigated by PET scan, fine needle aspirate or biopsy when possible before confirming the CR status.

### **6.4 Progression-free Survival**

Progression-free survival (PFS) is defined as the time from enrollment (i.e. assignment of patient ID number) to first documentation of objective tumor progression or to death due to any cause. Progression-free survival will also be examined as the interval from the date of the addition of paricalcitol upon progression of paclitaxel protein bound and gemcitabine and cisplatin to the earliest date of documented evidence of recurrent or progressive disease, or the date of death due to any cause, whichever occurs

first. For the estimation of progression-free and overall survival a Kaplan-Meier analysis will be performed.

In the absence of previous documentation of objective tumor progression will be censored at the last date the patient was known to be progression-free in patients who do not have objective tumor progression and who are: 1) still on study at the time of an analysis; 2) are given anti-tumor treatment other than the study treatment; or 3) are removed from study follow-up prior to documentation of objective tumor progression.

## **6.5 Survival**

Survival is defined as the time from enrollment (i.e. assignment of patient ID number) to date of death. In the absence of confirmation of death, survival time will be censored at the last date the patient is known to be alive. Overall survival will also be measured from the time of disease progression on paclitaxel protein bound and gemcitabine and cisplatin and those who then undergo therapy with paricalcitol.

## **6.6 Analysis Plan**

Continuous variables will be summarized using the mean (SD) or median (range). Frequency tables will be used to summarize categorical variables. Logistic regression will be used to assess the impact of patient characteristics on response and toxicity rates. The distribution of time-to-event endpoints (e.g. response duration, progression-free survival, overall survival) will be estimated using the Kaplan and Meier method. Cox (proportional hazards) regression will be used to evaluate multivariable predictive models of time-to-event outcomes.

## **6.7 Guidelines for Measuring Disease**

Antitumor activity will be evaluated by RECIST 1.1 criteria (Eisenhauer 2009). These response criteria are widely recognized and accepted as the standard criteria for determining response in patients with solid tumors.

## **6.8 Disease Definitions**

Measurable disease is defined as the presence of  $\geq 1$  measurable lesion. If the measurable disease is restricted to a solitary lesion, its neoplastic nature should be confirmed by cytology/histology.

At Baseline, tumor lesions will be categorized as:

- Measurable Lesions: lesions that can be accurately measured in at least one dimension (longest diameter in the plane of measurement is to be recorded) with a minimum size of:
  - 10 mm by CT scan (CT scan slice thickness no greater than 5 mm)
  - 10 mm caliper measurement by clinical exam (lesions which cannot be accurately measured with calipers should be recorded as non-measurable)
  - 20 mm by chest X-ray.
- Malignant lymph nodes: to be considered pathologically enlarged and measureable, a lymph node must be  $\geq 15$  mm in short axis when assessed by CT scan (CT scan slice thickness recommended to be no greater than 5 mm). At Baseline and follow-up, only the short axis will be measured and followed. or



- **Non-measurable Lesions:** all other lesions, including small lesions (longest diameter <10 mm or pathological lymph nodes with  $\geq 10$  to <15 mm short axis) as well as truly non-measurable lesions. Lesions considered truly non-measurable include: leptomeningeal disease, ascites, pleural/pericardial effusion, inflammatory breast disease, lymphangitis cutis/pulmonis, abdominal masses/abdominal organomegaly identified by physical exam that is not measurable by reproducible imaging techniques.

For special considerations regarding lesion measurability for bone lesions, cystic lesions and lesions with prior local treatment, consult the RECIST 1.1 guidelines in the Study Manual.

All measurements should be taken and recorded in metric notation using a ruler or calipers. All baseline evaluations should be performed as closely as possible to the beginning of treatment and never more than 4 weeks before beginning of treatment.

The same method of assessment and the same technique should be used to characterize each identified and reported lesion at baseline and during follow-up.

Clinical lesions will only be considered measurable when they are superficial (e.g. skin nodules and palpable lymph nodes). For the case of skin lesions, either a CT scan or documentation by color photography, including a ruler to estimate the size of the lesion, is to be done.

## 6.9 Methods of Measurement

Tumor measurements should be performed using the same method as well as the same staff member per patient, if possible, throughout the study. CT and MRI are the best currently available and reproducible methods to measure target lesions selected for response assessment. Conventional CT and MRI should be performed with cuts of 5 mm in slice thickness contiguously. This applies to tumors of the chest, abdomen, and pelvis.

As a rule, the minimum size of the lesion should be no less than double the slice thickness.

Lesions on chest x-rays are acceptable as measurable lesions when they are clearly defined and surrounded by aerated lung. However, CT is preferable.

Ultrasound should not be used to measure tumor lesions. It is, however, a possible alternative to clinical measurements of superficial palpable lymph nodes, subcutaneous lesions, and thyroid nodules. Ultrasound might also be useful to confirm the complete disappearance of superficial lesions usually assessed by clinical examination. If new lesions are identified by ultrasound in the course of the study, confirmation by CT or MRI is necessary.

Tumor markers alone cannot be used to assess objective tumor response. If markers are initially above the upper normal limit, they must normalize for a patient to be considered in complete clinical response. Cytology and histology can be used to differentiate between partial response (PR) and complete response (CR) in rare cases (e.g. after treatment to differentiate between residual benign lesions and residual malignant lesions in tumor types such as germ cell tumors) if required by protocol.

## 6.10 Baseline Documentation of “Target” and “Non-target” Lesions

- **Target Lesions:** all measurable lesions up to a maximum of 2 lesions per organ and 5 lesions in total, representative of all involved organs will be identified as target lesions and will be recorded

and measured at baseline. Target lesions should be selected on the basis of their size (lesions with the longest diameter [LD]), be representative of all involved organs, and their suitability for accurate repetitive measurements (either by imaging techniques or clinically). A sum of the LD for all target lesions will be calculated and reported as the baseline sum LD. The baseline sum of the LD will be used as reference to further characterize the objective tumor response.

- **Non-target Lesions:** all other lesions (or sites of disease) including pathological lymph nodes should be identified as non-target lesions and will also be recorded at baseline. Measurements of these lesions are not required, but the presence or absence of each should be noted throughout follow-up.

## 6.11 Response Criteria

Table 6. RECIST Target Lesion Response Criteria

Target Response Criteria	Definition
Complete Response (CR)	The disappearance of all target lesions and no new sites or disease-related symptoms confirmed at least 4 weeks after initial documentation. Any pathological lymph nodes (whether target or non-target) must have a reduction in short axis to < 10 mm. All sites must be assessed, including non-measurable sites, such as effusions, or markers.
Partial Response (PR)	At least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum of the diameters confirmed at least 4 weeks after initial documentation. PR is also recorded when all measurable disease has completely disappeared, but a non-measurable component (i.e., ascites) is still present but not progressing.
Stable Disease (SD)	Neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease.
Progressive Disease (PD)	At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum of the diameters recorded since on study (this includes the baseline sum if that is the smallest on study), which must also demonstrate an absolute increase of at least 5 mm; or the appearance of one or more new lesions;

Non-target lesion response will be classified according to the RECIST Non-Target Lesion Response Criteria in the following table.

Table 7. RECIST Non-target Lesion Response Criteria

Non-Target Response Criteria	Definition
Complete Response (CR)	Disappearance of all non-target lesions and normalization of tumor marker level confirmed at least 4 weeks after initial documentation. All lymph nodes must be non-pathological in size (< 10 mm short axis).

Non-Complete Response/Non-Progressive Disease (NonCR/Non-PD)	Persistence of one or more non-target lesions and/or the maintenance of tumor marker level above the normal limits.
Progressive Disease (PD)	Appearance of one or more non-target lesions and/or unequivocal progression of existing non-target lesions (“unequivocal progression” is defined as an overall level of substantial worsening in non-target disease that is of magnitude that, even in the presence of SD or PR in target disease, the treating physician would feel it important to change therapy).

## 6.12 Evaluation of Best Overall Response

The best overall response is the best response recorded from the start of the treatment until disease progression/recurrence (taking as reference for PD the smallest measurements recorded since the treatment started). In general, the patient’s best response assignment will depend on the achievement of both measurement and confirmation criteria.

Patients with a global deterioration of health status requiring discontinuation of treatment without objective evidence of disease progression at that time will be classified as having “symptomatic deterioration.” Every effort will be made to document the objective evidence of disease progression even after discontinuation of treatment.

In some circumstances, it may be difficult to distinguish residual disease from normal tissue. When the evaluation of complete response depends on this determination, it is recommended that the residual lesion be investigated (fine needle aspirate/biopsy) to confirm the complete response status.

Table 8. RECIST Overall Response Criteria

Target Response	Non-Target Response	New Lesions	Overall Response
CR	CR	No	CR
CR	non-CR/non-PD	No	PR
CR	Not Evaluated	No	PR
PR	Non-PD or not evaluated	No	PR
SD	Non-PD or not evaluated	No	SD
Not all evaluated	Non-PD	No	NE
PD	Any	Yes or No	PD
Any	PD	Yes or No	PD
Any	Any	Yes	PD

NE = inevaluable

## 6.13 Duration of Overall Response

The duration of overall response is measured from the time measurement criteria are met for CR or PR (whichever status is recorded first) until the first date that recurrence or PD is objectively documented, taking as reference for PD the smallest measurements recorded since the treatment started.

## 6.14 Duration of Stable Disease

Stable disease is measured from the start of the treatment until the criteria for disease progression are met, taking as reference the smallest measurements recorded since the treatment started.

For the purposes of this trial, the minimal time interval required between 2 measurements for determination of SD is 6 weeks (at least 2 consecutive assessments 6 weeks apart revealing SD). This time interval takes into account the expected clinical benefit that such a status may bring to the population under study.

## 7 SAFETY

The investigator is responsible for monitoring the safety of patients who have enrolled in the study. All adverse events (AEs) occurring after any administration of the study medication will be followed until the event resolves, until the patient begins alternative treatment, or until the end of the study. Investigators will grade AEs using the NCI CTCAE, version 4.0 (published 28 May 2009) (see Appendix D).

Investigators are required to document all AEs occurring during the clinical trial, commencing with the first dose of study medication and including the protocol-defined post-treatment followup period (21 CFR §312.64[b]) on designated CRF pages. AEs occurring following the signature of the informed consent, but prior to the first dose of study drug, will not be reported as AEs. It is also important to record all AEs that result in permanent discontinuation of the investigational product being studied, whether serious or non-serious.

Serious adverse events (SAEs), as defined below, must be reported to HONORHEALTH or its representative within 24 hours of knowledge of their occurrence.

### 7.1 Adverse Events

An AE is any unfavorable medical occurrence in a clinical investigation patient administered a pharmaceutical product, which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not considered related to the medicinal (investigational) product. All AEs, including observed or volunteered problems, complaints, or symptoms, are to be recorded on the CRF. Each AE is to be evaluated for duration, intensity, and causal relationship with the study medication or other factors.

Progression of disease is considered an efficacy outcome parameter and should not be captured as an AE.

A non-serious AE is any untoward medical occurrence that does not meet any of the criteria for SAEs.

Patients should be instructed to report any AE that they experience to the Investigator, starting from the time of their first dose. Investigators should assess AEs at each visit. AEs occurring during the clinical trial, starting at the time of the initial study drug infusion, and the follow-up period should be recorded on the appropriate AE page of the CRF.

Wherever possible, a specific disease or syndrome rather than individual associated signs and symptoms should be identified by the investigator and recorded on the CRF. However, if an observed or reported sign or symptom is not considered a component of a specific disease or syndrome by the investigator, it should be recorded as a separate AE on the CRF.

## 7.2 Serious Adverse Events

A serious adverse event (SAE) is any adverse experience occurring at any dose that results in any of the following outcomes:

- Death
- A life-threatening adverse event
- Life-threatening is defined as an event with immediate risk of death from the event as it occurred. It does not include an event that might have caused death if it occurred with a greater severity.
- In-patient hospitalization or prolongation of existing hospitalization
- Results in a persistent or significant disability/incapacity
- A congenital anomaly/birth defect
- Important medical events that may not be immediately life-threatening, or result in death or hospitalization, but may jeopardize the patient or may require intervention to prevent one of the other listed outcomes above.

## 7.3 Adverse Event Severity

AE will be graded according to the NCI CTCAE, Version 4.0 (see Appendix D)

- Grade 1 Mild AE
- Grade 2 Moderate AE
- Grade 3 Severe AE
- Grade 4 Life-threatening or disabling AE
- Grade 5 Death related to AE
- Severity versus Seriousness: Severity is used to describe the intensity of a specific event while the event itself, however, may be of relatively minor medical significance (such as severe headache). This is not the same as "seriousness," which is based on patient/event outcome at the time of the event. For example, the NCI CTCAE grade 4 (life-threatening or disabling AE) is assessed based on unique clinical descriptions of severity for each AE, and these criteria may be different from those used for the assessment of AE seriousness. An AE assessed as grade 4 based on the NCI CTCAE grades may or may not be assessed as serious based on the seriousness criteria.

## 7.4 Causality Assessment

The relationship of an AE to the study drug must be classified as one of the following:

- Unrelated: The AE is clearly not related to the study medication
- Possibly Related: The AE may be related to the study medication
- Definitely Related: The AE is clearly related to the study medication

## 7.5 Safety and Tolerance Analysis

The incidence of all AEs (regardless of causality) and all treatment-related AEs (those AEs thought to be possibly, probably, or definitely related to study drug) will be summarized by NCI CTCAE Version 4.0 term and maximum grade. The incidence of SAEs and AEs that lead to discontinuation of study drug will

also be summarized. Listings of patients who discontinue study drug due to an AE and patients with SAEs and deaths will be presented. Narratives will be provided for patients who experience an SAE.

#### 7.5.1 Laboratory Assessments

##### 7.5.1.1 Hematology Parameters

To investigate the maximal degree of myelosuppression, the [NCI CTCAE Version 4.0](#) grade for WBC, ANC, platelet count, and hemoglobin concentration will be summarized by the most severe grade in the first treatment cycle and by the most severe grade during the therapy for each treatment group; testing of treatment group differences will be performed using a CMH test. The incidence of patients with [NCI CTCAE Version 4.0](#) hematology values of Grade 3 or 4 that occurred after the first dose of study drug will be presented. Data for patients with Grade 3 or 4 hematology values will be listed.

##### 7.5.1.2 Clinical Chemistry

Liver and renal function will be summarized using the [NCI CTCAE Version 4.0](#) for alkaline phosphatase, ALT, AST, total bilirubin, BUN and creatinine. The number and percentage of patients who have more than one [NCI CTCAE Version 4.0](#) grade will be summarized using the most severe Grade for the first cycle of therapy and for anytime during therapy for each treatment group; testing of treatment group differences will be performed using a CochranMantel-Hanzel test. The incidence of patients with [NCI CTCAE Version 4.0](#) chemistry values of Grade 3 or 4 that occurred after the first dose of study drug will be presented. Data for patients with Grade 3 or 4 chemistry values will be listed.

##### 7.5.1.3 Peripheral Neuropathy

Peripheral neuropathy events will be captured according to protocol and reported by Investigators and investigative staff in accordance with adverse event and SAE reporting standards.

## 7.6 Patient Reporting of AEs and SAEs

Patients are to be encouraged to call the site to report any unexpected symptoms or problems they encounter between office visits. These events should be considered in the same fashion as if they had been reported at a scheduled office visit. At each scheduled office visit, after the patient has had an opportunity to spontaneously mention any problems, the Investigator should inquire about AEs by asking the following standard questions:

- Have you had any (other) medical problems since your last clinic visit?
- Have you taken any new prescribed or over-the-counter medicines or herbal/vitamin preparations, other than those given to you in this study, since your last visit/assessment?
- Have any new procedures been performed since your last study visit?

## 7.7 Investigator Reporting Serious Adverse Events

The Investigator is responsible for recording, reporting and following all Grade 3 or 4 AEs, regardless of causality, observed during the study period, starting with initial dose of study drug and ending at the time the patient goes off study or 30 days after patient's last dose of study drug, whichever is later. The Investigator should follow AEs until the event is resolved or stabilized, the patient is lost to follow-up, or

the event is otherwise explained. Events occurring within 30 days prior to study drug administration should be recorded as pre-treatment signs and symptoms. The only exception to this is for an AE that occurs prior to the first dose of study drug but is due to a procedure associated with assessments carried out to determine eligibility or to permit participation in this protocol – this should be recorded as an AE (rather than a pretreatment sign or symptom).

The Investigator or designee must completely and promptly record each AE in the source documentation, regardless of relationship to study drug as determined by the Investigator. Grade 3 and 4 AEs must be recorded in the CRF. The Investigator must assess AE/SAE causality for any patients treated at his/her site and for any patients treated under the direct care of his/her sub-Investigators. The Investigator should attempt, if possible, to establish a diagnosis based on the patient's signs and symptoms. When a diagnosis for the reported signs or symptoms is known, the Investigator should report the diagnosis, not the symptoms, as the AE.

Clinically significant laboratory abnormalities present at the baseline visit will be recorded as pre-treatment signs and symptoms.

Grade 3 and 4 adverse events and SAEs should be reported on the appropriate case report forms. In addition, all SAEs must be reported promptly to HonorHealth after the Investigator recognizes/classifies the event as a SAE. The specific reporting time frame depends on the type of SAE. For life-threatening or fatal events, the Investigator must report initial information on the SAE within 24 hours of becoming aware of the event, preferably by fax or alternatively by phone or email; at a minimum, a description of the event and the Investigator's judgment of causality must be provided at the time of the initial report.

Please report the event to: HonorHealth Drug Safety Team  
24 Hour Phone #: 480-323-1350  
Fax # : 480-323-1560  
Email: [DrugSafety@honorhealth.com](mailto:DrugSafety@honorhealth.com)

The Investigator should follow all AEs/SAEs observed during the study until they resolve or stabilize, the patient is lost to follow-up, or the events are otherwise explained.

For any additional questions regarding reporting requirements of a SAE, please contact the following individual:

Brandy Carothers  
Regulatory Affairs Coordinator  
HonorHealth Research Institute  
Tel. 480-323-1323  
E: [Brandy.Carothers@HonorHealth.com](mailto:Brandy.Carothers@HonorHealth.com)

## **7.8 IRB Notification of SAEs**

The Investigator is responsible for promptly notifying the IRB of all SAEs, including any followup information, occurring at his/her site and any SAE regulatory reports and Investigational New Drug Safety Reports that he/she receives from HonorHealth.

## **7.9 SAE Follow-Up**

For all SAEs occurring after first dose of study medication or within 30 days of the last administration of study medication, the investigator must submit follow-up reports to HonorHealth or its representative regarding the status of the SAE and the patient's subsequent course until the SAE has subsided, or until the condition stabilizes (in the case of persistent impairment), the patient receives alternative therapy, or the patient dies.

## **7.10 Sponsor Notification of Post-Study SAEs**

The Investigator should notify HonorHealth of any death or SAE occurring after a patient has withdrawn from the study, or after 30 days of the last study drug dose, whichever is later, when such death or SAE may reasonably be related to the medication used in the study. However, Investigators are not obligated to actively seek AEs in former study participants.

## **7.11 Pregnancy**

While not considered a SAE unless a serious criterion is met, pregnancies occurring in patients enrolled on the study or in their partners must be reported. The investigator should complete the pregnancy report form and fax it to HonorHealth within 24 hours of knowledge of the pregnancy.

# **8 ETHICAL, LEGAL, AND ADMINISTRATIVE ASPECTS**

## **8.1 Ethics**

### **8.1.1 Institutional Review Board/Ethics Committee Approval**

Before study initiation, this protocol and informed consent form will be submitted for review and approval to the IRBs charged with oversight for the clinical sites. In addition, any form of proposed advertising and advertising text for patient recruitment must be reviewed and approved by HonorHealth prior to submission to the IRB. The Investigator will forward to HonorHealth or Sponsor-nominated designee a copy of the IRB's approval of this protocol, any amendments, informed consent form, and any modifications to the informed consent, based on the FDA regulations set forth in 21 CFR 56 of the Code of Federal Regulations, as well as those of the applicable regulatory bodies in all other participating countries outside of the U.S.

In addition, the Investigator will be responsible for forwarding to HonorHealth a description of the IRB board members (including profession and affiliation) or a United States (US) Department of Health and Human Services (DHHS) General Assurance number and expiration date. If neither of these is available, the chairperson must submit a statement indicating that the members of the board responsible for the review meet FDA and other appropriate regulatory requirements. In addition, the labeling for all approved study drugs should be submitted to the IRB for informational purposes.

Clinical supplies will not be shipped to the clinical site until IRB approval is obtained for the protocol. Any existing amendments, informed consent, and photocopies of the approved documents must be received by HonorHealth or other sponsor-nominated designee prior to drug shipment.

### **8.1.2 Ethical Conduct of the Study**



This study will be conducted in compliance with the protocol, Good Clinical Practice (GCP), Guidelines of the International Conference on Harmonization (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use, and in full compliance with the World Medical Association Declaration of Helsinki and its most recent amendments.

### 8.1.3 Informed Consent

Written informed consent of the patient to participate in the study must be obtained and documented by the Investigator in accordance with the FDA regulations set forth in 21 CFR 50 as well as the applicable regulatory bodies in all other participating countries outside the United States.

The Investigator must provide the patient with a copy of the informed consent form in a language understandable to the patient. Written consent should be obtained before any protocol-required procedures are performed, including any procedure not part of normal patient care (e.g., withdrawal of current medications).

Changes made by a participating site to the recommended informed consent must be forwarded to HONORHEALTH for approval prior to submission to the corresponding IRB. A copy of the signed informed consent will be given to the patient or their legal representative and a copy must be retained in the Investigator's study records.

### 8.1.4 Data Safety and Monitoring

Because cancer is a life-threatening disease, treatments that result in Grade 3 and 4 toxicities are considered to have an acceptable risk profile. SAEs will be reported to the HonorHealth immediately and reviewed as they are received. Any unacceptable toxicities or severe toxicities that occur more frequently than expected will be discussed by the Lead Principal Investigator and the site Principal Investigators who will decide jointly whether the study should be modified, interrupted, or stopped. At least monthly conference calls will be held with investigators participating in the study.

## 8.2 Disclosure of Data

### 8.2.1 Study Data Monitoring Plan

Data monitoring procedures will be carried out by HonorHealth for all participating sites, and will be performed on a regular basis to comply with Good Clinical Practice guidelines.

Review of the case report forms, cross-reference with source documentation (including radiology review), review of study related regulatory documents and logs (e.g., enrollment, study site staff, drug accountability), and review of drug accountability will be monitored on an ongoing basis during monitoring sessions. The monitor will ensure that the investigation is conducted according to protocol design and regulatory requirements.

At the conclusion of the monitoring visit, the site monitor will meet with the site staff to discuss and request specific corrections to the case report forms, and/or request clarification, and/or additional source documentation. The site Clinical Research Coordinator responsible for the study will be provided with a copy of the written monitoring notes for resolution of the findings.

The HonorHealth site monitor will complete a written monitoring report and forward it to the site Principal Investigator and to the HonorHealth. The report will include a summary of what the site monitor reviewed and the site monitor's statements concerning the significant findings/facts, deviations and deficiencies,

conclusions, actions taken or to be taken, and/or actions recommended to ensure compliance. The site Principal Investigator will be expected to submit any Corrective Action Plans, in writing, to HonorHealth Administration and the HonorHealth site monitor. A copy of the monitoring forms, final monitoring reports, and Corrective Action Plan will be kept in the site monitor's study file at HonorHealth for follow-up at the next monitoring session.

### 8.2.2 Confidentiality

The Investigator and any other study personnel involved in this study shall not disclose, or use for any purposes (other than for the performance of this study), any data, records, or other information (hereinafter collectively "information") disclosed to the Investigator or other study personnel. Such information shall remain the confidential and proprietary property of HonorHealth, and shall be disclosed only to the Investigator or other designated study personnel.

The obligation of non-disclosure shall not apply to the following:

- relevant disclosure to potential study participants for the purpose of obtaining informed consent;
- information after such time that it is or becomes publicly available through no fault of the Investigator or other study personnel; and,
- information after such time that it is disclosed to the Investigator by a third party entitled to disclose such information.

If the study site is a 'covered site' under the definitions of the Health Insurance Portability and Accounting Act (HIPAA), the Investigator will ensure that the patient consents to the use of data by HonorHealth and its designees for the purposes of regulatory submissions, study publications, and drug approval.

### 8.2.3 Publication

This is an Investigator-led study. The data collected will not be used to license/register any pharmaceuticals.

Authorship of the final manuscript(s), interim publications, or abstracts will be decided according to active participation in the statistical design, the principal investigators, accrual of eligible patients and data analysis. Contributing centers and participating Investigators will be acknowledged in the final manuscript.

No participant may present data from his/her center separately from the rest of the study results unless approved by the other principal investigators.

SU2C will be notified of any outputs of the research such as guidelines, publications, presentation, changes in service delivery etc. prior to external submission or presentation.

In any oral or written report or poster presentation of Results or otherwise relating to the Research, the support of CRUK, SU2C and the Lustgarten foundation will be acknowledged, displaying the relevant logos where possible. Any publications resulting from research funded in whole or in part by the Grant must be cited as follows:

*"Research supported by a Stand Up To Cancer-Cancer Research UK-Lustgarten Foundation Pancreatic Cancer Dream Team Research Grant (Grant Number: 20-16). Stand Up To Cancer is a program of the Entertainment Industry Foundation. Research grants are administered by the American Association for Cancer Research, the scientific partner of SU2C".*

### **8.3 Protocol Compliance**

The investigator will conduct the study in compliance with the protocol given approval/favorable opinion by the IRB/IEC and the appropriate regulatory authority(ies). Changes to the protocol will require approval from HonorHealth, in addition to written IRB/IEC approval/favorable opinion prior to implementation, except when the modification is needed to eliminate an immediate hazard(s) to patients. The IRB/IEC may provide, if applicable regulatory authority(ies) permit, expedited review and approval/favorable opinion for minor change(s) in ongoing studies that have the approval /favorable opinion of the IRB/IEC. The investigator will submit all protocol modifications to HonorHealth and the regulatory authority(ies) in accordance with the governing regulations. Any departures from the protocol must be fully documented in the source documents.

### **8.4 On-site Audits**

Regulatory authorities, the IEC/IRB, and/or HonorHealth may request access to all source documents, data capture records, and other study documentation for onsite audit or inspection. Direct access to these documents must be guaranteed by the investigator, who must provide support at all times for these activities.

### **8.5 Premature Closure of the Study**

This study may be prematurely terminated, if in the opinion of the Lead Principal Investigator or HonorHealth, there is sufficient reasonable cause.

HonorHealth has the right to discontinue the study under the conditions specified in the clinical trials agreement. Written notification documenting the reason for study termination will be provided to the site investigator by the terminating party.

Circumstances that may warrant termination include, but are not limited to:

- Determination of unexpected, significant, or unacceptable risk to patients
- Failure to enter patients at an acceptable rate
- Insufficient adherence to protocol requirements
- Insufficient complete and/or evaluable data
- Plans to modify, suspend or discontinue the development of the drug

Should the study be closed prematurely, all study materials must be returned to HonorHealth.

### **8.6 Investigator Documentation**

#### **8.6.1 Form FDA 1572**

As this study has been determined to be IND Exempt and this is not a multi-center study, a 1572 will not be completed.

#### **8.6.2 Curriculum Vitae**

The Investigator must provide HonorHealth with his/her current signed and dated curriculum vitae and a current signed and dated curriculum vitae for each sub-Investigator. Current signed and dated curriculum vitae is defined as updated within 2 years of study start up.

#### **8.6.3 Financial Disclosures**

As a 1572 will not be completed for this study, Financial Disclosure forms will not be required or collected.

#### **8.6.4 Laboratory Certification and Normal Ranges**

The Investigator will provide a copy of all clinical laboratory certifications, certification numbers, dates of certifications, and a list of the normal ranges for all laboratory tests for all facilities listed. Updated versions of these documents must be provided to HonorHealth as appropriate. In the event the clinical laboratory is changed during the study, the study Principal Investigator will be notified. Appropriate documentation will be submitted to HonorHealth to verify the certification of the new laboratory.

All radiology facilities being utilized outside the investigative site must be pre-approved by HonorHealth.

### **8.7 Records Retention**

In accordance with applicable regulatory requirements, following closure of the study, the Investigator will maintain a copy of all site study records in a safe and secure location. HonorHealth will inform the Investigator of the time period for retaining these records in order to comply with applicable regulatory requirements.

HonorHealth reserves the right to terminate the study for refusal of the Investigator and/or investigational site to comply with any requirements stated in this study protocol.

### **8.8 Protocol Deviations**

Deviations from the protocol must be addressed as protocol amendments with IRB approval required prior to implementation. Apart from the regulatory requirements, it is vital to the success of the study that the Investigator adheres to the details of the protocol and thus holds to a minimum the number of cases that may be later classified as “incomplete,” “unusable,” or “not evaluable.”

## **9 DATA MANAGEMENT**

### **9.1 Patient Enrollment Instructions**

Patients must be registered within 5 working days prior to initiation of protocol therapy. Enrollment will be through the data management services of HonorHealth.

### **9.2 Data Submission Instructions**

This study uses a web based electronic data capture system for data submission through the data management services HonorHealth.

- Screening Form: at time of screening
- Enrollment Form: after eligibility confirmed.
- All screening/baseline/treatment/off-treatment Forms: within 2 weeks of occurrence.
- Adverse Event Form: within 2 weeks of each scheduled adverse events evaluation until adverse events have resolved following permanent discontinuation of treatment, documenting adverse event information, including toxicities indicated by lab testing. NOTE: all Serious Adverse Events must also be reported on the Adverse Event Form.
- Serious Adverse Events (SAE) documentation: submit directly to HonorHealth and the Lead Principal Investigator within the time frame and per the guidelines specified in Section 7.7. NOTE: all SAEs must also be reported on the Adverse Event Form.
- Notice of Death Form: within 2 weeks of knowledge of death.

## 10 TERMINATION OF STUDY

HonorHealth reserves the right to discontinue this study at any time.

## 11 INVESTIGATOR'S PROTOCOL AGREEMENT

The Investigator must sign the Investigator's Protocol Agreement. The original must be kept on file at HonorHealth and the Investigator must retain a copy. The completed Investigator's Protocol Agreement signifies agreement to comply with all procedures outlined by this protocol by the Investigator. An Investigator's Protocol Agreement must be signed if and when a protocol amendment is issued by HonorHealth.

## 12 REFERENCES

Assaf E, Verlinde-Carvalho M, Delbaldo C, Grenier J, Sellam Z, Pouessel D, Bouaita L, Baumgaertner I, Sobhani I, Tayar C, Paul M, Culine S. 5-Fluorouracil/Leucovorin Combined with Irinotecan and Oxaliplatin (FOLFIRINOX) as Second-Line Chemotherapy in Patients with Metastatic Pancreatic Adenocarcinoma. *Oncology* 2011;80:301-306.

Bellasi A, Galassi A, Salvi P, Cozzolino M. Paricalcitol and cardiorenal outcome: from the MPACT study to clinical practice. *Blood Purif* 2013; 36: 12-16.

Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. *J Clin Oncol.* 1997 Jun; 15(6):2403-13.

Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, Adenis A, Raoul J-L, Gourgou-Bourgade S, de la Fouchardière C, Bannoun J, Bachet J-B, Khemissa-Akouz F, Péré-Vergé D, Delbaldo C, Assenat E, Chauffert B, Michel P, Montoto-Grillot C, Ducreux M. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. *N Engl J Med.* 2011;364:1817-1825

Cozzolino M, Brancaccio D, Cannella G, Messa P, Gesualdo L, Marangella M, LoDeserto C, Pozzato M, Rombolà G, Costanzo AM, di Luzio Paparatti U, Mazzaferro S; FARO Study Group. VDRA therapy is

associated with improved survival in dialysis patients with serum intact PTH  $\leq$  150 pg/mL: results of the Italian FARO Survey. *Nephrol Dial Transplant*. 2012 Sep;27(9):3588-94.

Dragovich T: Pancreatic Cancer. eMedicine.Medscape.Com, 2012. Available from: <http://emedicine.medscape.com/article/280605>.

Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). *Eur J Cancer*. 2009 Jan; 45(2):228-47.

Fraschi G, Panza N, Comella P, Nicoletta GP, Natale M, Manzione L, Bilancia D, Cioffi R, Maiorino L, De Cataldis G, Belli M, Micillo E, Mascia V, Massidda B, Lorusso V, De Lena M, Carpagnano F, Contu A, Pusceddu G, Comella G. Cispatin, gemcitabine, and paclitaxel in locally advanced or metastatic non-small-cell lung cancer: A phase I-II study. *J Clin Oncology*. *Journal of Clinical Oncology*. 1999 Aug;17(8):2316-2325.

Frese KK, Neesse A, Cook N, Bapiro TE, Lolkema MP, Jodrell DI, Tuveson DA. Paclitaxel protein bound potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer. *Cancer Discovery*. 2012;2(3):OF1-OF10. DOI: 10.1158/2159-8290.CD-110242

Heinemann V, Boeck S, Hinke A, Labianca R, Louvet C. Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advance pancreatic cancer. *BMC Cancer*. 2008;28:82. DOI: 10.1186/1471-2407-8-82.

Jameson GS, Borazanci EH, Babiker HM, Poplin E, Niewiarowska AA, Gordon MS, Barrett MT, Ansaldo K, Lebron L, Stoll AC, Rosenthal A, Shemanski LR, Korn RL, Ramanathan RK, Von Hoff DD. A phase Ib/II pilot trial with nab-paclitaxel plus gemcitabine plus cisplatin in patients (pts) with stage IV pancreatic cancer. *Journal of Clinical Oncology* 35, no. 4\_suppl (February 2017) 341-341.

Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. *J Am Stat Assoc*. 1958;53:457-481.

Ketteler M, Martin KJ, Wolf M, Amdahl M, Cozzolino M, Goldsmith D, Sharma A, Marx S, Khan S. Paricalcitol versus cinacalcet plus low-dose Vitamin D therapy for the treatment of secondary hyperparathyroidism in patients receiving hemodialysis: results of the IMPACT SHPT study. *Nephrol Dial Transplant*. 2012 Aug;27(8):3270-8.

Lawrence JA, Akman SA, Melin SA, Caswe LD, Schwartz GG. Oral paricalcitol (19 nor-1 $\alpha$ , 25-dihydroxyvitamin D<sub>2</sub>) in women receiving chemotherapy for metastatic breast cancer: A feasibility trial. *Cancer Biol Ther* 14:476-80, 2013.

Liang WS, Craig DW, Carpten J, Borad MJ, Demeure MJ, Weiss GJ, Izatt T, Sinari S, Christoforides A, Aldrich J, Kurdoglu A, Barrett M, Phillips L, Benson H, Tembe W, Braggio E, Kiefer JA, Legendre C, Posner R1, Hostetter GH, Baker A, Egan JB, Han H, Lake D, Stites EC, Ramanathan RK, Fonseca R, Stewart AK, Von Hoff DD. Genome-wide characterization of pancreatic adenocarcinoma patients using massively parallel sequencing. *PLoS ONE*. 2012 Oct 10;7(10):e43192. doi:10.1371/journal.pone.0043192.

Meadors N, Floyd J, Perry MC. Pulmonary toxicity of chemotherapy. *Semin Oncol*. 2006;33(1):98-105.

Moore MJ, Goldstein D, Hamm J, et al.: Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. *J Clin Oncol*. 2007;25:1960-1966.

Reni M, Cereda S, Mazza E, Passoni P, Nicoletti R, Balzano G, Zerbi A, Arcidiacono PG, Staudacher C, Di Carlo V. PEGF (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) regimen as second-line therapy in patients with progressive or recurrent pancreatic cancer after gemcitabine-containing chemotherapy. *Am J Clin Oncol*. 2008;31:145-150.

Rowinsky EK, Donehower RC. Paclitaxel (taxol). *N. Engl J Med*. 1995;332(15):1004-14.

Schwartz GG, Hall MC, Stindt D, Patton S, Lovato J, Totri FM. Phase I/II study of 19-nor-1 $\alpha$ , 25-dihydroxyvitamin D2 (paricalcitol) in advanced androgen-insensitive prostate cancer. *Clin Cancer Res* 11:8680-5, 2005.

Sherman MH, Yu RT, Engle DD, Ding N, Atkins AR, Tiriach H, Collisson EA, Connor F, Van Dyke T, Kozlov S, Martin P, Tseng TW, Dawson DW, Donahue TR, Masamune A, Shimosegawa T, Apte MV, Wilson JS, Ng B, Lau SL, Gunton JE, Wahl GM, Hunter T, Drebin JA, O'Dwyer PJ, Liddle C, Tuveson DA, Downes M, Evans RM. Vitamin D receptor-mediated stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapy. *Cell*. 2014 Sep 25;159(1):80-93.

Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. *CA Cancer J Clin*. 2017 Jan;67(1):7-30.

Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L, Bennett CL, Cantor SB, Crawford J, Cross SJ, Demetri G, Desch CE, Pizzo PA, Schiffer CA, Schwartzberg L,

Somerfield MR, Somlo G, Wade JC, Wade JL, Winn RJ, Wozniak AJ, Wolff AC.. American Society for Clinical Oncology: 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. *J Clin Oncology*. 2006;24:31873205.

Tonbul HZ, Solak Y, Atalay H, Turkmen K, Altintepe L. Efficacy and tolerability of intravenous paricalcitol in calcitriol-resistant hemodialysis patients with secondary hyperparathyroidism: 12-month prospective study. *Ren Fail*. 2012;34(3):297-303.

Verbraecken J, Van De Heyning P, De Backer W, Van Gaal L. Body surface area in normalweight, overweight, and obese adults. A comparison study. *Metabolism*. 2006;55(4):515-24.

Von Hoff DD, Ramanathan RK, Borad MJ, Laheru DA, Smith LS, Korn RL, Trieu V, Iglesias JL, Zhang H, Soon-Shiong P, Shi T, Rajeshkumar NV, Maihtra A, Hidalgo M. Gemcitabine plus nabpaclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. *J Clin Oncol*. 2011;29:4548-4554.

Von Hoff DD, Ramanathan RK, Evans DB, Demeure MJ, Maney T, Wright B, Gatalica Z, McGinniss MJ. Actionable targets in pancreatic cancer detected by immunohistochemistry (IHC), microarray (MA) fluorescent in situ hybridization (FISH), and mutational analysis. *J Clin Oncology*. 2012;30s: abstr 4013.

Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, Harris M, Reni M, Dowden S, Laheru D, Bahary N, Ramanathan RK, Tabernero J, Hidalgo M,

Goldstein D, Van Cutsem E, Wei X, Iglesias J, Renschler MF. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. *N Engl J Med*. 2013 Oct 31;369(18):1691-703.



## 13 APPENDICES

### APPENDIX A: SCHEDULE OF EVENTS

#### Evaluations and Initial Treatment

Assessment	Screening Within 21 Days	Cycle 1			Cycle 2+			Prior to Cycles 4, 7, 10, etc.	End of Study or Early Termination <sup>11</sup>	Follow-up
		Day 1	Day 8*	Day 15*	Day 1	Day 8*	Day 15*			
Signed informed consent	X									
Review inclusion/exclusion	X	X								
Medical history <sup>1</sup>	X	X								
Physical examination	X	X	X	X	X	X	X		X	
Height (cm)	X									
Weight (kg)	X	X	X		X	X			X	
BSA calculation	X	X			X <sup>2</sup>					
Vital signs	X	X	X	X	X	X	X		X	
Karnofsky PS	X	X	X	X	X	X	X		X	
CT/ MRI scan / tumor measurements <sup>3</sup>	X							X	X	
ECG	X									
CBC w/differential	X	X	X	X	X	X	X		X	
Serum chemistries <sup>4</sup>	X	X	X	X	X	X	X		X	
PT/INR/aPTT	X									
CA 19-9 (or CA 125, or CEA if not expressers of CA 19-9)	X	X			X				X	
Vitamin D 25 OH	X	X			X					
Urinalysis <sup>5</sup>	X	X			X				X	
Fecal Swab	X	X			X				X	

Assessment	Screening Within 21 Days	Cycle 1			Cycle 2+			Prior to Cycles 4, 7, 10, etc.	End of Study or Early Termination <sup>11</sup>	Follow-up
		Day 1	Day 8*	Day 15*	Day 1	Day 8*	Day 15*			
Archived blocks of tumor specimen <sup>6</sup>	X									
Pregnancy <sup>7</sup>	X	X			X				X	
Concomitant medications <sup>8</sup>	X	X	X	X	X	X	X		X	X
Adverse events <sup>9</sup>		X	X	X	X	X	X		X	X
Exploratory Biomarkers <sup>10</sup>		X			X			X		
Telephone follow-up <sup>12</sup>										X
Pacitaxel Protein Bound <sup>13</sup>		X	X		X	X				
Cisplatin <sup>13</sup>		X	X		X	X				
Gemcitabine <sup>13</sup>		X	X		X	X				
Pre-cisplatin hydration		X	X		X	X				
Post-cisplatin hydration		X	X		X	X				
Neulasta			X (or D9)			X (or D9)				
NOTE: All assessments must be performed within 72 hour of each specified time parameter, except Cycle 1. *Day 8 physical examination as clinically indicated. Day 15 assessments as clinically indicated (see Section 5 for details).										
Neulasta may be given on Day 8 as ONpro (on-body injector kit) or Day 9										

### Treatment and Evaluations Upon Stable disease or Progression

Assessment	Cycle 1							Cycle 2+							Prior to Cycle 3	Prior to Cycles 4, 7, 10, etc.	End of Study or Early Termination <sup>22</sup>	Follow-up
	Day 1	Day 3	Day 5	Day 8*	Day 10	Day 12	Day 15*	Day 1	Day 3	Day 5	Day 8*	Day 10	Day 12	Day 15*				
Physical examination	X			X			X	X			X			X			X	
Weight (kg)	X			X				X			X						X	
BSA calculation	X							X <sup>14</sup>										
Vital signs	X			X			X	X			X			X			X	
Karnofsky PS	X			X			X	X			X			X			X	

Assessment	Cycle 1							Cycle 2+							Prior to Cycle 3	Prior to Cycles 4, 7, 10, etc.	End of Study or Early Termination <sup>22</sup>	Follow-up
	Day 1	Day 3	Day 5	Day 8*	Day 10	Day 12	Day 15*	Day 1	Day 3	Day 5	Day 8*	Day 10	Day 12	Day 15*				
CT/ MRI scan / tumor measurements <sup>15</sup>								X								X	X	
CBC w/differential	X			X			X	X			X			X			X	
Serum chemistries <sup>16</sup>	X			X			X	X			X			X			X	
CA 19-9 (or CA 125, or CEA if not expressers of CA 19-9)	X							X									X	
Parathyroid Hormone	X						X	X						X			X	
Vitamin D 25 OH	X							X										
Urinalysis <sup>17</sup>	X							X									X	
Pregnancy Urine	X							X									X	
Concomitant medications <sup>18</sup>	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X		X	X
Adverse events <sup>19</sup>	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X		X	X
Tumor Biopsies <sup>20</sup>	X														X			
Exploratory Biomarkers <sup>21</sup>	X															X		
Fecal Swab	X							X									X	
Telephone follow-up <sup>23</sup>																		X
Paclitaxel Protein Bound <sup>24</sup>	X			X				X			X							
Cisplatin <sup>24</sup>	X			X				X			X							
Gemcitabin <sup>24</sup>	X			X				X			X							
Paricalcitol <sup>25</sup>	X	X	X	X	X	X		X	X	X	X	X	X					
Pre-cisplatin hydration	X			X				X			X							
Post-cisplatin hydration	X			X				X			X							
Neulasta				X							X							
NOTE: All assessments must be performed within 72 hour of each specified time parameter, except Cycle 1. *Day 8 physical examination as clinically indicated. Day 15 assessments as clinically indicated (see Section 5 for details). Paricalcitol to be given upon stable disease or progression on Days 1,3,5, 8,10, 12 on cycles of treatment Neulasta may be given on Day 8 as ONpro (on-body injector kit) or Day 9																		

## Schedule of Events footnotes both tables

- To include concurrent baseline conditions (using NCI CTCAE, version 4.0), prior cancer therapy (including documentation of prior surgery, adjuvant or neoadjuvant chemotherapy and radiotherapy).
- BSA only needs to be changed if there has been a change >10% in body weight from Cycle 1-Day 1 (See Section 4.2).
- Computed tomography (CT) / magnetic resonance imaging (MRI) scan to document disease status (including chest, abdomen, pelvis, and other regions as clinically indicated. In addition, brain scan required to exclude brain metastases). If a CT scan was taken within 28 days prior to first dose, a new scan is not necessary. However, if a new scan is to be done, it should be performed within 5 days of starting chemotherapy. In addition to the CT / MRI scan, tumor size may also be assessed utilizing visual or palpable lesions

- on physical examination including full assessment of all known metastases (see RECIST 1.1 criteria in Section 7). Follow-up scans are due every 3 cycles or as clinically indicated (prior to cycle 4, 7, 10)
4. To include BUN, phosphorus, magnesium, creatinine, total protein, albumin, calcium, glucose, total bilirubin, alkaline phosphatase, AST, ALT, and electrolytes (chloride, sodium, potassium, and bicarbonate) and CA 19-9 (or CA 125, or CEA if not expressers of CA 19-9).
  5. Lab urinalysis to include protein, specific gravity, glucose, and blood.
  6. Archived paraffin block of tumor specimen, see lab manual
  7. Serum pregnancy at screening, urine pregnancy thereafter.
  8. To include all medications taken within 30 days prior to study enrollment.
  9. Patient will be followed until resolution of any drug-related AE or SAE occurring during the study, including, within 30 days of last administration of study medication, or when the patient begins alternative therapy; whichever is sooner.
  10. Refer to accompanying lab manual
  11. End of Study or Early Termination assessments can be completed 14-28 (+/- 2) days from the last dose of study medication
  12. Follow-up assessments by telephone will be conducted in all patients every 12 weeks to determine date of response, date of disease progression, and date of death.
  13. The sequence of drug administration is paclitaxel protein bound, then cisplatin, then gemcitabine. Initiation of each cycle of treatment may be given a 48 hour window.
  14. BSA only needs to be changed if there has been a change >10% in body weight from Cycle 1-Day 1 (See Section 4.2).
  15. Computed tomography (CT) / magnetic resonance imaging (MRI) scan to document disease status (including chest, abdomen, pelvis, and other regions as clinically indicated. In addition, brain scan required to exclude brain metastases). If a CT scan was taken within 28 days prior to first dose, a new scan is not necessary. However, if a new scan is to be done, it should be performed within 5 days of starting chemotherapy. In addition to the CT / MRI scan, tumor size may also be assessed utilizing visual or palpable lesions on physical examination including full assessment of all known metastases (see RECIST 1.1 criteria in Section 7). Follow-up scans are due every 3 cycles or as clinically indicated (prior to cycle 4, 7, 10)
  16. To include BUN, phosphorus, magnesium, creatinine, total protein, albumin, calcium, glucose, total bilirubin, alkaline phosphatase, AST, ALT, and electrolytes (chloride, sodium, potassium, and bicarbonate) and CA 19-9 (or CA 125, or CEA if not expressers of CA 19-9).
  17. Lab urinalysis to include protein, specific gravity, glucose, and blood.
  18. To include all medications taken within 30 days prior to study enrollment.
  19. Patient will be followed until resolution of any drug-related AE or SAE occurring during the study, including, within 30 days of last administration of study medication, or when the patient begins alternative therapy; whichever is sooner.
  20. Tumor biopsies as in Section 5.3 and in lab manual. To be done upon initiation of paricalcitol and 6 weeks later (+/- 1 week)
  21. Refer to accompanying lab manual
  22. End of Study or Early Termination assessments can be completed 14-28 (+/- 2) days from the last dose of study medication
  23. Follow-up assessments by telephone will be conducted in all patients every 12 weeks to determine date of response, date of disease progression, and date of death.
  24. The sequence of drug administration is paclitaxel protein bound, then cisplatin, then gemcitabine. Initiation of each cycle of treatment may be given a 48 hour window.
  25. Paricalcitol will be given on stable disease or disease progression of paclitaxel protein bound, cisplatin, and gemcitabine on days 1,3,5, 8,10, and 12 of every cycle (+/- 2 days).

## APPENDIX B: KARNOFSKY PERFORMANCE STATUS

Karnofsky Performance Status		
	Score	Descriptions
Able to carry on normal activity and to work; no special care needed.	100	Normal: no complaints; no evidence of disease
	90	Able to carry on normal activity; minor signs or symptoms of disease
	80	Normal activity with effort; some signs or symptoms of disease
Unable to work; able to live at home and care for most personal needs; varying amount of assistance needed.	70	Cares for self; unable to carry on normal activities or to do active work
	60	Requires occasional assistance, but is able to care for most of personal needs
	50	Requires considerable assistance and frequent medical care
Unable to care for self; requires equivalent of institutional or hospital care; disease may be progressing rapidly.	40	Disabled: requires special care and assistance
	30	Severely disabled: hospital admission is indicated although death not imminent
	20	Very sick: hospital admission necessary; active supportive treatment needed
	10	Moribund: fatal processes are progressing rapidly
	0	Dead

## APPENDIX C: LIST OF ABBREVIATIONS

Term	Definition
Abraxis	Abraxis BioScience, Inc
ADR	Adverse Drug Reaction
AE	Adverse Event
ALT (SGPT)	Alanine Aminotransferase (SGPT)
ANC	Absolute Neutrophil Count
ASCO	American Society of Clinical Oncology
AST (SGOT)	Aspartate Aminotransferase (SGOT)
AUC	Area Under the Curve
BCC	Basal Cell Carcinoma
β-hCG	Beta subunit of human chorionic gonadotrophin (hCG)
BMS	Bristol-Myers Squibb
BSA	Body Surface Area
BUN	Blood Urea Nitrogen
°C	Degrees Celsius
CA 125	Cancer Antigen 125
CA19-9	Carbohydrate Antigen 19-9
CBC	Complete Blood Count
CEA	Carcinoembryonic antigen
CFR	Code of Federal Regulations
CGH	Comparative Genomic Hybridization
CI	Confidence Interval
CIB	Clinical Investigator's Brochure
C <sub>max</sub>	Maximum observed plasma concentration
CMH	Cochran-Mantel-Haenszel
CML	Chronic myelogenous leukemia
CrEL	Cremophor-EL

<b>Term</b>	<b>Definition</b>
CRF	Case Report Form
CR	Complete Response
CRO	Contract Research Organization
CT	Computed Tomography
CTCAE	Common Terminology Criteria for Adverse Events
DHHS	Department of Health and Human Services
DLT	Dose Limiting Toxicity
DMC	Data Monitoring Committee
DVT	Deep Vein Thrombosis
ECG	Electrocardiogram
eCRF	Electronic Case Report Form
EPR	Enhanced Permeability and Retention
EORTC	European Organization for Research and Treatment of Cancer
EORTC QLQ-C30	Questionnaire to assess quality of life of patients with cancer
EORTC QLQ-BM22	EORTC QLQ Bone metastases module
EOS	End of Study
FAS	Full Analysis Set
°F	Degrees Fahrenheit
FDA	United States Food and Drug Administration
GCP	Good Clinical Practice(s)
G-CSF	Granulocyte Colony-Stimulating Factor
GFR	Glomerular Filtration Rate
GTX	Gemzar plus Taxotere plus Xeloda
HA	Human Albumin
HBsAg	Hepatitis B surface antigen
HCV	Hepatitis C antibody
Hgb	Hemoglobin
Hh	Hedgehog

<b>Term</b>	<b>Definition</b>
HIV	Human Immunodeficiency Virus
ICH	International Conference on Harmonisation
IEC	Independent Ethics Committee
IND	Investigational New Drug
INR	International Normalized Ratio
IRB	Institutional Review Board
IV	Intravenous(ly)
KPS	Karnofsky Performance Status
LDH	Lactate Dehydrogenase
MedDRA	Medical Dictionary for Regulatory Activities
MR	Minor Response
MRI	Magnetic Resonance Imaging
MTD	Maximum Tolerated Dose
NCI	National Cancer Institute
NCI-CTCAE	National Cancer Institute Common Terminology Criteria for Adverse Events
ND	Not Done
NIH	National Institutes of Health
non-DEHP	Non-(di(2-ethylhexyl) phthalate)
ORR	Overall Response Rate
PD	Progressive Disease
PET	Positron-Emission Tomography
PFS	Progression Free Survival
P-gp	P-glycoprotein
PK	Pharmacokinetics
PPS	Per Protocol Set
PR	Partial Response
PT	Prothrombin Time
PTT	Partial Thromboplastin Time



<b>Term</b>	<b>Definition</b>
QD	Daily
RECIST	Response Evaluation Criteria in Solid Tumors
SAE	Serious Adverse Event
SAF	Safety Analysis Set
SAP	Statistical Analysis Plan
SCLC	Small-cell lung cancer
SD	Stable Disease
S.D.	Standard Deviation
SGOT	Serum Glutamate Oxaloacetic Transaminase
SGPT	Serum Glutamate Pyruvic Transaminase
SOP	Standard Operating Procedure
SPARC	Secreted Protein Acidic and Rich in Cysteine (a glycoprotein)
SUV	Standard Uptake Value
T <sub>max</sub>	Time of Maximum Observed Plasma Concentration
TEAE	Treatment Emergent Adverse Event
TEAV	Treatment Emergent Abnormal Laboratory Value
TKI	Tyrosine Kinase Inhibitor
TTP	Time to Progression
ULN	Upper Limit of Normal
US	United States
WBC	White Blood Cell
WCBP	Women of Child-Bearing Potential
WHO	World Health Organization
WHODD	WHO Drug Dictionary

## **APPENDIX D: REVISED NATIONAL CANCER INSTITUTE COMMON TERMINOLOGY CRITERIA FOR ADVERSE EVENTS (NCI CTCAE), VERSION 4.0 (PUBLISHED 28 MAY 2009)**

### **Revised National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 4.0 (published 28 May 2009)**

The National Cancer Institute (NCI) Cancer Therapy Evaluation Program (CTEP) Common Terminology Criteria for Adverse Events (CTCAE), version 4.0 can be viewed on-line at the following NCI web site:

[http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE\\_4.03\\_2010-06-14\\_QuickReference\\_8.5x11.pdf](http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf)

## **APPENDIX E: STUDY DRUG PREPARATION, DOSING, ADMINISTRATION AND STORAGE**

See links below to website access

Paclitaxel Protein bound (Abraxane™) Prescribing Information (Updated 1/2012) – Accessed via Abraxane Website: [http://www.abraxane.com/docs/Abraxane\\_PrescribingInformation.pdf](http://www.abraxane.com/docs/Abraxane_PrescribingInformation.pdf)

Cisplatin Prescribing Information (updated 2012) – Accessed via Daily Med (National Library of Medicine) <http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a440f077-46f6-4688-a20965bce38d1c92>

Gemcitabine (Gemzar™) Prescribing Information (Updated 2/2011) – Accessed via Gemzar Website: <http://pi.lilly.com/us/gemzar.pdf>

Paricalcitol (Zemlar®) Prescribing Information (Updated 2012) – Accessed via Zemlar Website <http://www.zemlar.com/>

## APPENDIX F: 2006 UPDATE OF ASCO PRACTICE GUIDELINE RECOMMENDATIONS FOR THE USE OF WHITE BLOOD CELL GROWTH FACTORS: GUIDELINE SUMMARY

Setting/Indication	Recommendation
Primary prophylaxis	Primary prophylaxis is recommended for the prevention of FN in patients who have a high risk of FN based on age, medical history, disease characteristics, and myelotoxicity of the chemotherapy regimen. For “dose-dense” regimens, CSF is required and recommended. Clinical Trial data support the use of CSF when the risk of FN is in the range of 20% or higher.
Primary prophylaxis: Special circumstances	Certain clinical factors predispose to increased complications from prolonged neutropenia, including: patient age > 65 years; poor performance status; previous episodes of FN; extensive prior treatment including large radiation ports; administration of combined chemoradiotherapy; bone marrow involvement by tumor-producing cytopenias; poor nutritional status; the presence of open wounds or active infections; more advanced cancer, as well as other serious comorbidities. In such situations, primary prophylaxis with CSF is often appropriate, even with regimens with FN rates of < 20%.
Secondary prophylaxis	Secondary prophylaxis with CSF is recommended for patients who experienced a neutropenic complication from a prior cycle of chemotherapy (for which primary prophylaxis was not received), in which a reduced dose may compromise disease-free or overall survival or treatment outcome. In many clinical situations, dose reduction or delay may be a reasonable alternative.
Therapeutic use: Afebrile neutropenia	CSF should not be routinely used for patients with neutropenia who are afebrile.
Therapeutic use: Febrile neutropenia	CSF should not be routinely used as adjunctive treatment with antibiotic therapy for patients with fever and neutropenia. However, CSF should be considered in patients with fever and neutropenia who are at high-risk for infection-associated complications, or who have prognostic factors that are predictive of poor clinical outcomes. High-risk features include expected prolonged (> 10 days) and profound ( $< 0.1 \times 10^9/L$ ) neutropenia, age > 65 years, uncontrolled primary disease, pneumonia, hypotension and multi-organ dysfunction (sepsis syndrome), invasive fungal infection, or being hospitalized at the time of the development of fever.

Setting/Indication	Recommendation
Dose intensity/density of chemotherapy Adjuncts to progenitor-cell transplantation	Dose-dense regimens should only be used within an appropriately designed clinical Trial or if supported by convincing efficacy data.  Administration of CSF to mobilize PBPC often in conjunction with chemotherapy, and their administration after autologous, but not allogeneic, PBPC transplantation is the current standard of care.
AML: Initial or repeat induction chemotherapy	CSF use following initial induction therapy is reasonable, though there has been no favorable impact on remission rate, remission duration, or survival. Patients > 55 years of age may be most likely to benefit from CSF use.
AML: CSF for priming effects	Use of CSF for priming effects is not recommended.
AML: Consolidation chemotherapy	CSF use can be recommended after the completion of consolidation chemotherapy because of the potential to decrease the incidence of infection and eliminate the likelihood of hospitalization in some patients receiving intensive postremission chemotherapy. There seems to be more profound shortening of the duration of neutropenia after consolidation chemotherapy for patients with AML in remission than for patients receiving initial induction therapy. As yet there is no information about the effect of longer-acting pegylated CSFs in patients with myeloid leukemias, and they should not be used in such patients outside of clinical Trials.
MDS	Intermittent administration of CSF may be considered in a subset of patients with severe neutropenia and recurrent infection.
ALL	CSF administration is recommended after the completion of the initial first few days of chemotherapy of the initial induction or first postremission course, thus shortening the duration of neutropenia of < 1,000/mm <sup>3</sup> by approximately 1 week.
Acute leukemia in relapse	CSF should be used judiciously, or not at all, in patients with refractory or relapsed myeloid leukemia since the expected benefit is only a few days of shortened neutropenia.
Radiotherapy ± chemotherapy	CSF should be avoided in patients receiving concomitant chemotherapy and radiation therapy, particularly involving the mediastinum. In the absence of chemotherapy, therapeutic use of CSF may be considered in patients receiving radiation therapy alone if prolonged delays secondary to neutropenia are expected.

Setting/Indication	Recommendation
Older patients	Prophylactic CSF for patients aged $\geq 65$ years with lymphoma treated with curative chemotherapy (CHOP or more aggressive regimens) should be given to reduce the incidence of FN and infections.
Pediatric patients	As in adults, the use of G-CSF is reasonable for the primary prophylaxis of pediatric patients with a likelihood of FN. Similarly, the use of G-CSF for secondary prophylaxis or for therapy should be limited to high-risk patients. However, the potential risk for secondary myeloid leukemia or myelodysplastic syndrome associated with G-CSF represents a concern in children with ALL whose prognosis is otherwise excellent. For these reasons, the specific use of G-CSF in children with ALL should be considered carefully.
Comparative clinical activity of G-CSF and GM-CSF	No guideline recommendation can be made regarding the equivalency of the two colony-stimulating agents. Further Trials are recommended to study the comparative clinical activity, toxicity, and cost-effectiveness of G-CSF and GM-CSF.
Treatment for radiation injury	Current recommendations for the management of patients exposed to lethal doses of total-body radiotherapy, but not doses high enough to lead to certain death due to injury to other organs, includes the prompt administration of CSF or pegylated G-CSF.

Abbreviations: CSF, colony-stimulating factors; FN, febrile neutropenia; PBPC, peripheral-blood progenitor cell; AML, acute myeloid leukemia; MDS, myelodysplastic syndrome; ALL, acute lymphocytic leukemia; CHOP, cyclophosphamide, doxorubicin, vincristine, prednisone; G-CSF, filgrastim; GM-CSF, sargramostim; pegylated G-CSF, pegfilgrastim.

## APPENDIX G: MEMO FOR DEXAMETHASONE DOSE REDUCTION WITH CONCOMITANT ADMINISTRATION OF FOSAPREPITANT

The current protocol recommends the following prophylactic medication regimen:

*Aloxi (palonosetron) 0.25mg IV, **Emend (fosaprepitant) 150 mg IV and dexamethasone 20mg IV** within 30 minutes prior to treatment on days 1 and 8, repeated every 21 days. Patients will continue oral antiemetic prophylaxis at home with ondansetron 8mg bid and dexamethasone 4mg bid for 2 days after chemotherapy.*

Fosaprepitant is a moderate inhibitor of CYP3A4, resulting in an increased serum concentration of dexamethasone. The dose of dexamethasone, especially on day 1 and day 8, must be decreased to account for the drug-drug interaction.

Per EMEND® Prescribing Information for the 150mg (Single Dose Regimen of EMEND):

*EMEND for Injection 150 mg is administered intravenously on Day 1 only as an infusion **over 20-30 minutes** initiated approximately 30 minutes prior to chemotherapy. No capsules of EMEND are administered on Days 2 and 3. EMEND for Injection should be administered in conjunction with a corticosteroid and a 5-HT3 antagonist as specified in Table 1.*

<b>Table 1</b> <b>Recommended dosing (Single Dose Regimen of EMEND) for the prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy</b>				
	Day 1	Day 2	Day 3	Day 4
EMEND	150 mg intravenous	none	none	none
Dexamethasone*	12 mg orally	8 mg orally	<b>8 mg orally twice daily</b>	<b>8 mg orally twice daily</b>
5-HT3 antagonist	See the package insert for the selected 5-HT3 antagonist for appropriate Dosing information.	none	none	none

\* Dexamethasone should be administered 30 minutes prior to chemotherapy treatment on Day 1 and in the morning on Days 2 through 4. **The dose of dexamethasone accounts for drug interactions.**

Due to similar bioavailability of oral and IV dexamethasone, the IV dexamethasone dose should be decreased to 12mg as recommended. The protocol has already conservatively adjusted the dose of oral dexamethasone on days 2 and 3 of treatment to 4mg BID. The next protocol amendment will reflect this recommendation.

Karen Ansaldo, PharmD, BCPS  
 Virginia G. Piper Cancer Center Clinical Trials  
 Scottsdale Healthcare  
 10510 N. 92<sup>nd</sup> St., Suite 200  
 Scottsdale, AZ 85258